



CURRICULUM VITAE

Ali Khamesipour, PhD

Professor, Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, 415 Taleghani Avenue, P.O. Box 14155-6383, Tehran 1416613675, Iran

Phone: (98-21) 8897 0657, mobile # 98 912145 9634

Faxphone: (98-21) 8897 0658/8895 3804

Email address: ali.khamesipour@gmail.com, Khamesipour@tums.ac.ir, Khamesipour_ali@yahoo.com

I. PERSONAL

Date and Place of Birth: January 10, 1951, Isfahan, Iran

Present Home Address: No. 21, 22nd Avenue,

Sanaee Street, 14188, Tehran, Iran

Phone: (98-21) 8883 3870, 8882 1180

Married, three children

Nationality: Iranian

Expertise: GCP clinical trials of vaccines and drugs from Phase-1 to Phase 3, Experimental and clinical Immunology, protocol development, data management and ethics.

II. EDUCATION

Post-doctoral fellowship 8/1992 - 8/1993

University of California, Irvine, College of Medicine, Department of Pathology, Irvine, California, USA

PhD, Department of Medical Microbiology and Immunology, School of Medicine,

Southern Illinois University, Springfield, Ill. (1992)

Advisor: Professor and Head Dept., Morris D. Cooper PhD

Major: Microbiology and Immunology

MSPH, Department of Pathobiology, School of Public Health, Tehran University (1979)

Major: Pathobiology, Advisor: Farrokh Modabber PhD

BS, School of Medicine, Isfahan University, Iran (1976)

Major: Medical Technology

III. ADDITIONAL TRAINING

Prospective Workshop on *Leishmania* aetiology: Current Trends and Future Perspectives, 14-15 November 2007, Antwerpen, Belgium.

Workshop on "Essentials of Strategic Management", Organized by Ministry of Health and Medical Education, 23-26 February 2003, Tehran, Iran.

Workshop on "Sampling Techniques", Organized by School of Public Health, Tehran University of Medical Sciences, 4-7 January 2003, Tehran, Iran.

Workshop on "Evidence Based Medicine", Organized by School of Public Health, Tehran University of Medical Sciences, TUMS, 7-11 December 2002, Tehran, Iran.

Workshop on "Designing and Developing Clinical Trials", Organized by WHO/TDR, Ouro Preto, Brazil, 17-20 April 2000.

Refresher course on Immunology, Vaccinology, and Biotechnology Applied to Infectious Diseases, Organized by WHO and International Society of Immunology, Pune, India 24 November to 10 December 1999.

Workshop on "Good Clinical Practice (GCP) for Clinical Monitors", Organized by WHO/TDR, Dizin, Iran, 17-22 July 1999.

Workshop on "Field Efficacy Trial against Leishmaniasis", Organized by WHO/TDR, Dizin, Iran, 11-22 October 1993.

Workshop on "Radiation Safety", University of California at Irvine, Irvine, CA, USA, August 1992.

Workshop on "Laboratory animal handling", University of California at Irvine, Irvine, CA, USA, September 1992.

V. PROFESSIONAL EXPERIENCE

Professor 2011 - present

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Associated professor 2005 - 2011

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Assistant professor 1993 - 2005

Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran

Visiting Professor 1995-1998

Department of Biological Sciences, University of North Texas, Denton, Texas, USA,

Research Fellow, 5/1988 - 7/1992

Southern Illinois University, School of Medicine, Department of Medical, Microbiology and Immunology, Springfield, Illinois USA

Teaching Assistant 8/1987 - 5/1988

Southern Illinois University, Department of Microbiology, Carbondale, Illinois USA

Medical Laboratory Supervisor 12/1976 - 3/1986

Baharlou Hospital, Tehran University of Medical Sciences, Tehran, Iran

Clinical Laboratory Supervisor, 11/1983 - 4/1985

Public Health Clinic, Tehran, Iran

Research Assistant, 10/1976 - 6/1980

Tehran University, School of Public Health, Pathobiology Department, Tehran, Iran

Blood Bank Technician, 6/1974 - 5/1976

Isfahan University Hospital, Isfahan, Iran

IV. TEACHING EXPERIENCE:

Workshop on "2nd International Training Course in Leishmaniasis Management and Control

19 June – 16 July 2011, Tehran, Iran, training on GCP, June 30 to July 2, 2011, Organized by WHO/EMRO and MoH (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy and Kerman University of Medical Sciences, Kerman, Iran, 17-19 April 2008 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Ahwaz University of Medical Sciences, Ahwaz, Iran, 22-25 February 2008 (facilitator).

Prospective Workshop on Leishmaniasis, Antwerp 14th-15th November 2007

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran, 31 January to 2 February 2006 (facilitator).

Workshop on "Authorization/Evaluation on Clinical Trials" Organized by World Health Organization, Immunization, vaccines and Biologicals Strengthening National Regulatory System, Shiraz, Iran, 10-14 July 2004 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Tabriz University of Medical Sciences, Tabriz, Iran, 10-12 Dec. 2003 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Research Institute of Medical Parasitology, Samarkand, Uzbekistan, 12- 21 August 2003. (Organizer and facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by Center for Research and Training in Skin Disease and Leprosy, Kerman University of Medical Sciences, Kerman, Iran, 2-4 July 2003 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by World Health Organization/Tropical Diseases Research, Center for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran, 4-6 May 2003 (facilitator).

Workshop on "Training Course on Good Clinical Practice (GCP)", Organized by World Health Organization/Tropical Diseases Research, Tehran, Iran, 24-26 April 2002 (facilitator).

Workshop on "Introduction to proposal/protocol development", Organized by World Health Organization/Tropical Diseases Research, Tehran, Iran, 5-9 November 2000 (facilitator).

Teaching Microbiology course for DDS student, Department of Microbiology, SU, Carbondale, IL, USA, 1987.

Teaching Molecular Microbiology course and Microbiology Lab for graduate student of Zoology, Department of Microbiology, SIU, Carbondale, IL, USA, 1987.

V. MEMBERSHIP IN PROFESSIONAL ASSOCIATIONS:

Chair of National Leishmaniasis Network, since 2013-present

National Committee on Leishmaniasis management, 2008-present

International research reference group on Leishmaniasis and Human African Trypanosomiasis, and Chagas Disease, TDR/WHO, 2008-present

The Vienna Vaccine Safety Initiative, Implementation Working Group, 2007-present

Member of Research Council of National Molecular Medicine Network, since 2005-present

The Brighton Collaboration/allergy working group 2002-present

WHO/TDR Member Product Development Team, Leishmaniasis Vaccine. 1998-2002

WHO/TDR Steering Committee on *Leishmaniases* (observer) 1997

National Committee on *Leishmaniases* 1994-1998

National Committee on Tuberculosis 1994-1995

American Society for Microbiology 1988 -1998

VI. ADDITIONAL PROFESSIONAL ACTIVITIES:

NASZA Dermatologia Online, Our Dermatology online 2010-present

Editorial Board of Clinical Reviews and Opinions, 2009-present

Editorial Board of Iranian Journal of Arthropod-Borne Diseases, 2007-present

Editorial board, Iranian Journal of Dermatology, 1998-present

Board of consultants, Medical Journal of the Islamic Republic of Iran, 1997-2000

VII. ORAL PRESENTATION AND ABSTRACT

High level of arsenic and lead in a meglumine antimonite product used in a Middle Eastern country, 5th World Cong. on Leishmaniasis, Porto de Galinhas, Pernambuco, Brazil, 13-17 May 2013,

Current and future treatment options, Int. Cong. of Derm. Cosm. & Laser, Tehran, Iran, 10-12 Oct 2012

Leishmaniasis Vaccine and Human Immune Responses in Cutaneous Leishmaniasis, The 1st Int. & 8th Nat. Cong. of Parasitology & Parasitic Dis., Kerman, Iran, 16-18, Oct 2012

Inactivated vaccines and leishmanizations: a historical view of vaccination for Leishmaniasis in the world, The 2nd Int. Symp. on Leishmaniasis Vaccines, Ouro Preto -MG –Sep. 1-6, 2012

Leishmanization: Reasons to use or not to use, Pre-Symposium Courses, The 2nd Int. Symp. on Leishmaniasis Vaccines, Ouro Preto -MG -1-6, Sep 2012

Leishmaniasis vaccine: A brief history, 2nd Int. Training Course on Leishmaniasis Management and Control, Tehran, Iran, 19 June –16 July 2011

Treatment Trials and vaccine development trials. Immunopathogenesis and Novel Treatment Strategies of Cutaneous Leishmaniasis, Erlangen, Germany, 10-11 Nov, 2010

First generation Leishmaniasis Vaccines: a review of efficacy field trials. Reunião de Pesquisa Aplicada em Doença Leishmanioses, Uberaba/Minas Gerais, Brazil 26-29 Oct 2010

A brief history of leishmanization: *Leishmania* vaccine, achievements and failures, 7th World Congress on Vaccines, Immunization and Immunotherapy, Berlin, Germany, 26-28 May 2010

History of Vaccination for Leishmaniasis, Inter. Symp. on Leishmaniasis Vaccines, Recife, Brazil, 9 –11 March, 2009.

Comparison of the efficacy of weekly intralesional injections of meglumine antimoniate with twice a week injections in the of acute anthroponotic cutaneous Leishmaniasis treatment.

4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Leishmanization as a prophylactic tool/evaluation of *Leishmania* vaccine, International Workshop on *Leishmania*, Pasteur Institute of Iran, Tehran, Iran, March 1-6 2008.

Old World Leishmaniasis Vaccine, 21st World Congress of Dermatology, Buenos Aires, Argentina, 30 Sep-5 Oct 2007

Clinical trial on efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous Leishmaniasis (ACL) caused by *L. tropica*, Razi Cong. of Derm. Tehran Iran, 25-27 April 2007.

Evaluation of Leishmaniasis vaccines by using live challenge (leishmanization), Razi Cong. of Derm, Tehran Iran, 25-27 April 2007.

Overview of Vaccines against Leishmaniasis, 10th Cong. of the Pan Arab League of Derm., Pan Arab League of Derm., Softel Hotel, Taiz, Yemen, 31 Aug-4 Sep. 2006

Paromomycin Ointment, Trials in Iran, Consultative Meeting on DNDi Strategy for treatment of Cutaneous Leishmaniasis (CL) including Post Kala-azar Dermal *Leishmania* (PKDL), Mucosal Leishmaniasis (ML) and Diffuse CL, Institute Pasteur, Paris, 13-15 June, 2006.

Summary of vaccine development with emphasis on Leishmaniasis vaccine, 8th Iranian Cong. of Immun & Allergy, Tehran, Iran 17-20 May 2006.

Leishmaniasis vaccines in Iran-treatment and vaccine trials, Zum Seminar, 15 Sep. 2005, Freiburg, Germany

First generation vaccines, Vaccine approaches against parasitic diseases, Foundation Merieux, Les Pensieres, Veyrier-Du-Lac 7-9, Sep. 2005

Current experience with *Leishmania* vaccines, Consultation Meeting on Live *Leishmania* vaccines, Geneva, Switzerland, 3-4 June 2005

Differential immune responses to vaccination in populations of non endemic vs. endemic areas, 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Imiquimod Cream, Trials in Iran, 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Comparison of combination of Imiquimod cream and Glucantime with Glucantime alone in cutaneous Leishmaniasis. 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Comparison of leishmanin skin test by using four different antigens prepared from *L. major* and *L. tropica*. 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Correlation of CD26 expression on CD4⁺ T cell with IFN- γ production in cutaneous Leishmaniasis. 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Cytokine profile and CD26 expression on CD4⁺ T cells in non-healing and healing form of cutaneous Leishmaniasis. 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Evaluation of immune response against Leishmaniasis induced by liposomes containing freeze/thawed thimerosal treated *L. major* (KLM) in C57bl/6 mice. 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

The status of cutaneous Leishmaniasis after the earthquake in Bam, Iran, 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Vaccination of Balb/c mice against cutaneous Leishmaniasis (CL) using liposomes containing recombinant major surface Glycoprotein of *Leishmania* (rgp63) and CpG ODNs, 3rd World Cong. on Leishmaniasis, Palermo-Terrasini, Sicily, Italy, 10-15 April, 2005

Leishmania vaccine studies in Old World, 13th Cong. Of European Academ. Of Dermat. & Vener, Florence, Italy, 17-21 Nov. 2004

Leishmanization a method for protection and evaluation of candidate vaccines against Leishmaniasis, 9th European Multicolloquium of Paras, Valencia, Spain: 23 July 2004.

Identification of *Leishmania* isolated from cutaneous Leishmaniasis patients in Isfahan, Iran by using monoclonal antibodies. 9th European Multicolloquium of Paras., Valencia, Spain: 23 July 2004.

Induction of partial protection against *L. major* infection in Balb/c mice immunized with Alum precipitated autoclaved *L. major* mixed with either *M. vaccae* or BCG, 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Evaluation of cell mediated immunity against Leishmaniasis by liposome encapsulated with autoclaved *L. major* (ALM) precipitated with Alum. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Leishmania vaccine around the world and in Iran.

New findings in Cutaneous Leishmaniasis, Dermatology Conf., 24-25 April 2003, Isfahan Iran

Iran trial, Phase I-II with leishmanization. WHO/TDR/PRD Leishmaniasis vaccine PDT meeting, 24-25 Oct. 2002, Geneva, Switzerland

Evaluation of *Leishmania* vaccine by using live challenge (leishmanization). 6th Iranian Cong. of Immun. & Aller. May 2002, Tehran, Iran.

Presentation of clinical trials in Iran. Joint TDR & IDRI *Leishmania* vaccine clinical trial meeting, 6-7 December, 2001, Geneva, Switzerland.

Presentation of current clinical trials in Iran. WHO/TDR/PRD *Leishmaniavaccine* PDT meeting, December 5th, 2001, Geneva, Switzerland.

Leishmanization (LZ) as a tool for control of Leishmaniasis and for evaluation of candidate vaccine against Leishmaniasis. World Leish 2, 20-24 May 2001, Crete, Greece.

Autoclaved *L. major* (ALM) mixed with BCG against Zoonotic Cutaneous Leishmaniasis (ZCL). 3rd Product Development Team meeting on Leishmaniasis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

Leishmanization as challenge for evaluation of candidate vaccine and for protection against *Leishmaniases*. 3rd Product Development Team meeting on Leishmaniasis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

Ongoing trials in Iran, 2nd Product Development Team meeting on Leishmaniasis vaccine, TDR/WHO, 14-16 October 1999, Bailadores, Venezuela.

Effects of cytokines on Chlamydial infection in human fallopian tubes. The 4th Inter. Cong. of Immun. & Allergy, 13-15 May 1998, Isfahan, Iran.

Phase III efficacy trial of multiple doses of autoclaved *L. major* plus BCG. 1st Product Development Team meeting on Leishmaniasis vaccine, TDR/WHO, 24-27 September 1998, Quito, Ecuador.

Prevention of cutaneous Leishmaniasis and progress in vaccine development. 4th Intern. Cong. in Dermat. 8-10 Oct. 1997 Tehran, Iran.

Safety and immunogenicity of three injections of autoclaved *L. major* in leishmanin negative and positive school children.

1st World Congress on Leishmaniasis, May 5-9, 1997, Istanbul, Turkey

Comparison of three types of leishmanins: standard, autoclaved and freeze-thawed. 1st World Congress on Leishmaniasis, May 5-9, 1997 Istanbul, Turkey

Phase I-II safety and immunogenicity of multiple doses of autoclaved *L. major* plus BCG in children. WHO/TDR Steering committee meeting, Istanbul, Turkey, May 2-4, 1997

Comparison of Specificity and Sensitivity of Two Types of Leishmanin (autoclaved *L. major* and thimerosal treated *L. major*). The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Abstracts

Khamesipour A, Khatami AR, Eskandari SE, Ghoorchi MH, Bahrami M, Gorouhi F, Javadi A, Nassiri-Kashani M, Firooz AR, Sharifi I, Fekri AR, Dowlati Y. Randomized open-labeled controlled clinical trial on efficacy of oral miltefosine in comparison with meglumine antimoniate in the treatment of acute Anthroponotic Cutaneous Leishmaniasis (ACL).

4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Sharifi I, Aflatoonian MR, Fekri AR, **Khamesipour A**, Cutaneous Leishmaniasis in Bam: Five years before and after the earthquake. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Khamesipour A, Khatami AR, Eskandari SE, Ghoorchi MH, Bahrami M, Gorouhi F, Javadi A, Nassiri-Kashani M, Firooz AR, Sharifi I, Fekri AR, Jalali M, Dowlati Y. Comparison of the efficacy of weekly intralesional injections of meglumine antimoniate with twice a week injections in the of acute anthroponotic cutaneous Leishmaniasis treatment.

4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Badiee A, Jaafari MR, **Khamesipour A**, Samiei A, Soroush D, Evaluation of immune response and protection extent against Leishmaniasis in BALB/c mice immunized with liposomal rgp63: The role of liposome size. 4th World Cong. Leishmaniasis, Lucknow, India, 3-7 February 2009.

Hejazi SH, Zia Jahromi N, Bandehpour M, Eslami G, Salehi R, **Khamesipour A**, Kazemi B.

Gene cloning of Iranian *Leishmania major* mannose-1-phosphate guanyltransferase. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Jaafari MR, Bavarsad N, Fazly Bazzaz BS, Samiei A, Soroush D, Ghorbani S, Lotfi heravi MM, **Khamesipour A**. The effect of Topical liposomes containing Paromomycin Sulfate (PM) in the treatment of *L. major* infected Balb/c mice. 4th World Cong on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Jaafari MR, Badiee, **Khamesipour A**, Samiei A, Soroush D, Tavassoti Kheiri M, Barkhordari F, Mahboudi F, Immunization of BALB/c mice against Leishmaniasis using LPD Nanoparticles Containing rgp63 and rLmaCIN Prepared with CpG Oligodeoxynucleotides. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Sharifi I, Shokri A, **Khamesipour A**, Fasihi Harandi M. The synergistic effect of verapamil on *in vitro* susceptibility of promastigote and amastigote of *L. tropica* to meglumine antimonite. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Eskandari SE, Azimzadeh A, Bahar M, Safai Naraghi Z, Javadi A, Mohammadi A, **Khamesipour A**. The effect of microwave and/or infrared radiation in the treatment of Balb/c mice lesion induced by *L. major*. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 Feb 2009.

Sharifi I, Fekri AR, Jalali MS, Saberi S, Nilforoshzadeh MA, Zolfaghari A, Shirani L, Abdian N, Siadat AH, Hejazi SH, **Khamesipour A**, Study of therapeutic effects of thyme, yarrow, hennah and garlic extract on mice cutaneous Leishmaniasis. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Eslami G, Salehi R, Hejazi SH, **Khamesipour A**, Kazemi B. Characterization of a novel TRYP6 from *Leishmania*

major (MRHO/IR/75/ER). 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Hejazi SH, Eslami G, Nilforoshzadeh MA, Sayareh S, Saberi S, Ghaffari Sh, Abdian N, Siadat AH, **khamesipour A.** Relative frequency of palpebral Leishmaniasis and its ocular effects in Esfahan, Iran. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Mortazavi H, Heidari B, **khamesipour A.** Vasheghani-Farahani A. Study of non-healing cutaneous leishmaniasis in Razi skin hospital, Tehran, Iran: A 10 year study. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Nateghi-Rostami M, **khamesipour A.** Keshavarz H, Eskandari SE, Mohammadi A. CD4+/CD8+ T cell responses to live or killed *Leishmania major* differently. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Akhavan AA, **Khamesipour A,** Habibi Gh, Mohammadi AM, Eskandari SE, Hosseini-najad Z. Identification of causative agents of cutaneous Leishmaniasis using a standard PCR method in Iran. 4th World Congress on Leishmaniasis, Lucknow, India, 3-7 February 2009.

Jaafari MR., Badiee A., **Khamesipour A,** Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., Mahboudi F., Enhancement of immune response in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of *Leishmania* (rgp63): The role of bilayer composition. Annual Meeting of Inter. Liposome Society, 8-11 Dec., 2007, London, UK.

Nassiri-kashani M., Firooz AR., Davari P., Ghorchi MH., Eskandari SE., Goroohi F., **Khamesipour A.,** khatami AR, Bahrami M., Javadi A., Dowlati Y., Evaluation of meglumine antimoniate effect on liver, kidney and pancreas function tests in patients with cutaneous Leishmaniasis. Journal of Investigate Dermatology 2007-10-26.

Khamesipour A., Bahrami M., Ghorchi MH., Eskandari SE., khatami AR, Firooz AR., Nassiri-kashani M., Dowlati Y., Goroohi F., Clinical trial on efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous Leishmaniasis (ACL) caused by *L.tropica*, Razi Congress of Dermatology, Tehran Iran, 25-27 April 2007.

Khamesipour A, Nassiri-kashani M., Emamjomeh M., Firooz AR., Shafie A., Rahimi E., Esksndari SE., Mohammadi A., Dowlati Y., Goroohi F., Evaluation of Leishmaniasis vaccines by using live challenge (leishmanization), Razi Congress of Dermatology, Tehran Iran, 25-27 April 2007.

Nassiri Kashani M., Firooz AR., Eskandari SE., Ghoorchi MH., **Khamesipour A.,** Khatami AR., Javadi A., Dowlati Y., Evaluation of effects of intramuscular meglumine antimoniate (Glucantime®) injections on liver, kidney and pancreas function serum markers in patients with cutaneous Leishmaniasis. 10th Congress of the Pan Arab League of Dermatology, Pan Arab League of Dermatology, Softel Hotel, Taiz, Yemen, 31 August to 4 September 2006

Hejazi SH., Bakhshizadeh M., Eslami G., **Khamesipour A,** The effect of a nitric oxide releaser on healing of *Leishmania* lesion in murine animal. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 August 2006

Hadighi R., Mohebbali M., **Khamesipour A,** Ouellette M., *In vitro* anti *Leishmanial* effect of different drugs on SbV resistant *Leishmania tropica* field isolates. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 August 2006

Hejazi SH., Eslami G., Malekaneh M., **Khamesipour A.,** ELISA technique for detection of anti-*Leishmania* Abs using anti-mouse IgG conjugated by penicillinase. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 Aug 2006.

Fata S, Javadi Z, Berneje F., **Khamesipour A.,** Ganjbakhsh M, Akbari M and Fata A., Diffuse cutaneous Leishmaniasis due to misdiagnosis. ICOPA XI, Secc, Glasgow, Schotland, 6 -11 Aug 2006.

Mortazavi H., Asadi Z., Samimi F., **Khamesipour A,** Value of histopathology in diagnosis of cutaneous Leishmaniasis (CL): A 10 year review of slides of patients with primary diagnosis of CL. 3rd World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Firooz, A., Khatami A., **Khamesipour A,** Nilforoushzadeh M., Nassiri-Kashani M., Behnia F., Pazoki-Toroudi H., Dowlati Y. Comparison of intralesional injections of 2% zinc sulfate solution with Glucantime in the treatment of cutaneous Leishmaniasis. 3rd World Congress on leishmaniosis, April 10-15, 2005 Palermo-Terrasini, Sicily, Italy

Hejazi H., Tolouie S., Mostaghim M., Asilian A., Shatalebi MA., **Khamesipour A**, Effect of a new physical form of paromomycin sulfate mixed with gentamicine on growth of *Leishmania major*. 3rd World Congress on leishmaniosis, April 10-15, 2005Palermo-Terrasini, Sicily, Italy

Badiee A., Jaafari MR., Samiei A., Soroush D., Webb J., **Khamesipour A**. Immunization of Balb/c mice against cutaneous Leishmaniasis (CL) using liposomes containing rLmstI1 and CpG-ODN. 3rd World Congress on leishmaniosis, April 10-15, 2005Palermo-Terrasini, Sicily, Italy

Shazad B., **Khamesipour A**, Abbaszadeh B., Modabber F., Cutaneous Leishmaniasis lesion is more severe in residence of non-endemic area exposed to *Leishmania*. 3rd World Congress on leishmaniosis, April 10-15, 2005Palermo-Terrasini, Sicily, Italy

Jandaghi J., Moshiri E., Shenaei SY., Sayyadnejad HA., Hosseini SJ., Hooshmand B., **Khamesipour A**, Spread of zoonotic cutaneous Leishmaniasis to new foci of Iran. 3rd World Congress on leishmaniosis, April 10-15, 2005Palermo-Terrasini, Sicily, Italy

Ajdari S, **Khamesipour A**, Jafari Shakib R, Mohtasham Amiri Z, Nikbin B, Correlatoin of CD26 expression on CD4+ T cell with IFN- γ production in cutaneous Leishmaniasis 2005 Third world congress on Leishmaniasis, Sicily, Italy

Jafari Shakib R, **Khamesipour A**, Ajdary S, Mohtasham Amiri Z, Nikbin B, Cytokine profile and CD26 expression on CD4+ T cells in non-healing and healing form of cutaneous Leishmaniasis 2005 Third world congress on Leishmaniasis, Sicily, Italy

Hejazi H, **Khamesipour A**, Bonakdar Sakhi HR, Eslami G. Comparison of *Leishmania* skin test by using four different antigens prepared from *L. major* and *L. tropica*. Medicine and Health in the Tropics. September, 11-15 2005. Marseille, France.

Eidsmo L., Nylen S., Khamensipour A., Chiodi F., Akuffo H. Fas Mediated Apoptosis during Human *L. major* Infection. 12th Inter. Cong. of Immun. July 2004

Jafari-Shakib R., Ajdari S., **Khamesipour A**, Shokrgozar MA., Mortazavi H., Amirzargar AA., Nikbin B. Changes in Plasma Soluble CD26 and CD30: The Marker of Th1/Th2 Balance in Cutaneous Leishmaniasis. 12th Inter. Cong. of Immun. July 2004

Sohrabi Y., Jaafari MR., Mohammadi AM., Eskandari SE., **Khamesipour A**. Induction of Cell Mediated Immunity Against Leishmaniasis Using Mannan Coated Liposomes Encapsulated with Autoclaved *Leishmania major*. 12th Inter. Cong. of Immun. July 2004

Hejazi SH., Jamali S., Tashakor N., **Khamesipour A**. Identification of *Leishmania* species by PCR technique in Isfahan, Iran. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Keshavarz H., Nateghi Rostami M., **Khamesipour A**. Draining lymph node parasite burden in Balb/c mice immunized with alum precipitated autoclaved *L. major* and challenged with *L. major*. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Nateghi Rostami M., Keshavarz H., **Khamesipour A**. Comparative analysis of the adjuvant activity of *Mycobacterium vaccae* and BCG mixed with Alum precipitated autoclaved *L. major* vaccine (Alum-ALM) in murine model of leishmaniasis. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Eskandari ES., Keshavarz H., **khamesipour A**., Nateghpour M. The prevalence of *Toxoplasma* and risk factors in Iran. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sharifi I., Aflatonian MR., **Khamesipour A**, Nadim A., Keshavarz H., Raesi A., Malaria and cutaneous Leishmaniasis control programs after earthquake in Bam, Iran. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sharifi I., Aflatonian Mr., **Khamesipour A**, Ahmadi-Mousavi MR., Nadim A., Keshavarz H., Raesi A., Zamani G. Epidemiology, knowledge, perceptions, practices, and GIS for control and management of malaria in rural communities of Kahnouj in southern Iran. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sohrabi Y., Jaafari MR., Miramin Mohammadi A., Eskandari SE., Javadi A., **Khamesipour A**. Evaluation of immune response induced by freeze/thawed thimerosal treated *L. major* (KLM) in murine model of Leishmaniasis. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Mohebalia M., **Khamesipour A**, Mobedi I., Zarei Z., Hashemi-Fesharki R., Javadian E. Double blind randomized

efficacy field trial of alum precipitated autoclaved *Leishmania major* vaccine mixed with BCG against canine visceral Leishmaniasis in Meshkin-shahr district I.R. Iran. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Tashakor N., Kalantari M., Hejazi SH., **Khamesipour A.** Induction of protection against *L. major* infection in BALB/c mice by inoculation of low doses of *L. major*. 9th European Multicolloquium of Parasitology, Valencia, Spain: 23 July 2004.

Sohrabi, Y., Jaafari, MR., MirAmin-Mohammadi, A., **Khamesipour A.** Induction of cell mediated immunity against Leishmaniasis using mannan coated liposomes containing autoclaved *Leishmania major*. 6th International conference Liposome advances; progress in drug and vaccine delivery, 15-19 Dec., 2003, London, UK

Khamesipour A., Jaafari, MR., MirAmin-Mohammadi, A., Sohrabi, Y., Immunization of Balb/c mice with liposomes/autoclaved *Leishmania major* (ALM) composed of different phospholipids. 6th International conference Liposome advances; progress in drug and vaccine delivery, 15-19 Dec., 2003, London, UK

Badami, B., **Khamesipour A.**, Amin Harati F. Study of urethral Chlamydial infection in men with Non-gonococcal urethritis in Tehran, Iran, 13th ECCMID May 10-13, 2003, Glasgow, UK

Khamesipour A., *Leishmania* vaccine around the world and in Iran.

New findings in Cutaneous Leishmaniasis, Dermatology, 24-25 April 2003, Isfahan Iran

Musa, AM., Khalil, EAG., Ismail, A., Fesharki, H., **Khamesipour A.**, Modabber F., Elhassan IM., El-Hassan AM. Immunochemotherapy of Patients with persistent post kala-azar dermal Leishmaniasis (PKDL): a pilot study of safety and possible efficacy. Endemic and Infec. Dis. Conf., Khartoum, Sudan 5 May 2003.

Dowlati, Y., **Khamesipour A.**, Immunology and vaccination, 20th Congress of Dermatology, 1-5, 2002, Paris, France.

Mortazavi, H., Dowlati, Y., **Khamesipour A.**, Hillarie, Z., Cutaneous Leishmaniasis: Comparison of Interferon- γ production in chronic non-healing versus self healing cases. 11th Congress of the EADV, Prague 2002

Khamesipour A., Modabber, F., Dowlati, Y., Nassiri-Kashani, Firooz, A., M., Hashemi-Fesharki, R., Mousavi, SM., Farzan, Z., MirAmin-Mohammadi, A., Shakib, R., Javadi, A., Hejazi, H., Leishmanization Evaluation of *Leishmania* vaccine by live challenge (leishmanization). Iranian J. Aller. Asth. & Immun. Sup. May 2002.

Khamesipour A., Iran trial, Phase I-II with leishmanization. WHO/TDR/PRD Leishmaniasis vaccine PDT meeting, 24-25 Oct. 2002, Geneva, Switzerland

Khamesipour A., Evaluation of *Leishmania* vaccine by live challenge (leishmanization). 6th Iranian Cong. of Immun. & Aller. May 2002, Tehran, Iran.

Khamesipour A., Presentation of clinical trials in Iran. Joint TDR & IDRI *Leishmania* vaccine clinical trial meeting, 6-7 December, 2001, Geneva, Switzerland.

Khamesipour A., Presentation of current clinical trial in Iran. WHO/TDR/PRD *Leishmania* vaccine PDT meeting, December 5th, 2001, Geneva, Switzerland.

Firooz, A., **Khamesipour A.**, Fallah, N., Dowlati, Y. The effect of treatment with itraconazole on quality of life of patients with toenail onychomycosis, European Academy of Dermatology and Venerology JEADV 15 (Suppl. 2) 104-274, 2001

Khamesipour A., Dowlati, Y., Asilian, A., Hashemi-Fesharki, R., Modabber, F. Leishmanization (LZ) as a tool for control of Leishmaniasis and for evaluation of candidate vaccine against Leishmaniasis. World Leish 2, 20-24 May 2001, Crete, Greece.

Khamesipour A., Dowlati, Y., Hejazi, H., Nassiri-Kashani, M., Firooz, A., late Jalayer, T., Modabber, F. Protective efficacy of multiple doses of a *Leishmania major* vaccine mixed with BCG in zoonotic cutaneous Leishmaniasis (ZCL) endemic area. World Leish 2, 20-24 May 2001, Crete, Greece.

Khamesipour A., Dowlati, Y., Nilforoushzadeh, M., Javadi, A., Hejazi, H., Naseri, Q., Sharifi, I., Moulton, L., Zicker, F., Smith, P. G., Modabber, F., Phase III efficacy field trial of multiple doses of a *Leishmania major* vaccine mixed with BCG in children in zoonotic cutaneous Leishmaniasis (ZCL) endemic area. World Leish 2, 20-24 May 2001, Crete, Greece.

Alimohammadian, M. H., **Khamesipour A.**, Sacks, D., Darabi, H., Firooz, A., Malekzadeh, Sh., Dowlati, Y., and Modabber, F., The role of BCG in immune responses induced by multiple doses of autoclaved *Leishmania major*

vaccine mixed with BCG injections. World Leish 2, 20-24 May 2001, Crete, Greece.

Jaafari, M. R., **Khamesipour A**, Hamedivafa, F., Koushbaghi, M., Inducing cell mediated immunity in Balb/c mice using liposomes encapsulated with crude *Leishmania* antigens(CLA). World Leish 2, 20-24 May 2001, Crete, Greece.

Mahmoodi, M., **Khamesipour A**, Dowlati, Y., Sharifi, I., Rafati, S., and Modabber, F., Immune responses measured in human volunteers vaccinated with *Leishmania major* vaccine mixed with BCG. World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Zemani, F., Nadim, A., **Khamesipour A**, Nassiri, K.M., Dowlati, Y., Ardehali, S., Modabber, F., Identification and characterization of cutaneous Leishmaniasis species in Kerman province, Southeast Iran, World Leish 2, 20-24 May 2001, Crete, Greece.

Mahmoodi, M., **Khamesipour A**, Dowlati, Y., Sharifi, I., Rafati, S., and Modabber, F., T cell responses in cutaneous Leishmaniasis: Comparison of non-healing patients and cases with previous positive leishmanin skin test with individuals cured from the disease. World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Nadim, A., **Khamesipour A**, Nassiri, K.M., Moulton, L., Zicker, F., Smith, P. G., Dowlati, Y., Modabber, F., Multiple doses of autoclaved *Leishmania major* vaccine against anthroponotic cutaneous Leishmaniasis in Bam, Iran, World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Mahboodi, F., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Nadim, A., **Khamesipour A**, Nassiri, K.M., Dowlati, Y., Modabber, F., Lupoid Leishmaniasis in school children in Bam, south-east Iran. World Leish 2, 20-24 May 2001, Crete, Greece.

Sharifi, I., Fekri, A., Aflatonian M. R., Ahmadi-Mousavi, M.R., Nadim, A., **Khamesipour A**, Nassiri, K.M., Dowlati, Y., Zicker, F., Modabber, F., Leishmanin skin test reactivity in primary school children in the South-eastern city of Bam.

World Leish 2, 20-24 May 2001, Crete, Greece.

Habibi, G.R., **Khamesipour A**, Mahboodi, F., Cytokine gene expression in nonhealed and healed cutaneous Leishmaniasis in response to *in vitro* stimulation with recombinant gp63 using quantitative RT-PCR. World Leish 2, 20-24 May 2001, Crete, Greece.

Mortazavi, H., **Khamesipour A**, Ajdary, S., Nazemi, M.J., Clinico-immunological features of chronic non-healing cases of cutaneous Leishmaniasis (CL) and their responses to therapy: Report of 12 cases. World Leish 2, 20-24 May 2001, Crete, Greece.

Khamesipour A, Autoclaved *L. major* (ALM) mixed with BCG against Zoonotic Cutaneous Leishmaniasis (ZCL). 3rd Product Development Team meeting on Leishmaniasis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

Khamesipour A, Leishmanization as challenge for evaluation of candidate vaccine and for protection against *Leishmaniasis*. 3rd Product Development Team meeting on Leishmaniasis vaccine meeting, TDR/WHO, 2-5 July 2000, Isfahan, Iran.

Habibi, G.R., **Khamesipour A**, Mahboodi, F., Evaluation of cytokine gene expression in nonhealed Leishmaniasis patients with quantitative RT-PCR methodology. Iranian J. of allergy, asthma & immunology, Supplement 1, May 17-19, 2000, Tehran, Iran.

Hejazi, S.H., Kalantari, M., Jalayer, T., Havaee, S.A., **Khamesipour A**, Establishment of protection immunity against cutaneous Leishmaniasis by low dose of *L. major* in Balb/c mice. Iranian J. of allergy, asthma & immunology, Supplement 1, May 17-19, 2000, Tehran, Iran.

Momeni, A.Z., **Khamesipour A**, Bagherzadeh, A., Aminjavaheri M., Reaction to different antigens in cutaneous Leishmaniasis. Iranian J. of allergy, asthma & immunology, Supplement 1, May 17-19, 2000, Tehran, Iran.

Habibi, G.R., **Khamesipour A**, Mahboodi, F., Evaluation of cytokine gene level expression in leishmanin positive and leishmanin negative individuals with use of RT-PCR technique. Proceeding of the 1st National Congress of Biotechnology, 1: 520-527, Feb 22-24, 2000, Tehran, Iran.

Khamesipour A, Ongoing trials in Iran. 2nd Product Development Team meeting on Leishmaniasis vaccine, TDR/WHO, 14-16 October 1999, Bailadores, Venezuela.

Khamesipour A, Ongoing trial in Iran. Product Development Team (PDT) TDR/WHO meeting, 14-16 October

1999, Bailadores, Venezuela.

Khamesipour A., and Cooper, MD. Effects of cytokines on Chlamydial infection in human fallopian tubes. The 4th Inter. Cong. of Immun. & Allergy, 13-15 May 1998, Isfahan, Iran.

Khamesipour A., and M. D. Cooper. Effects of cytokines on Chlamydial infection in human fallopian tubes. The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Mahmoodi, M., **Khamesipour A.**, Rafati, S., Momeni AZ., Hashemi-Fesharaki R., Hejazi, Hejazi, H., Emmamjomeh, M., and Dowlati Y. Search for Surrogate marker (s) of immunity following injection of autoclaved *Leishmania major* vaccine plus BCG.

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Hejazi, S. H., **Khamesipour A.**, Alimohammadian M. H., Allameh, A. Jalayer, T. and Dowlati, Y. Protection effect of fractions from *Leishmania* antigen against Leishmaniasis in Balb/c mice.

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Momeni, AZ, Jalayer T., Emamjomeh, M., **Khamesipour A.**, Labaf Ghasemi R., Dowlati Y., Sharifi I., Aminjavaheri M., Shafiei A., Modabber F. Efficacy trial of single dose of killed *L. major* vaccine against natural zoonotic cutaneous Leishmaniasis (randomized double blind study).

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Fallah, E., Edrisian, GH., Hajjarian, H., Rad, M., Jamshidi, SH., Nadim, A., and **Khamesipour A.** Immune responses against *Leishmania* vaccines in vaccinated dogs with autoclaved *L. infantum* and *L. major* mixed with BCG in Iran.

The 4th International Congress of Immun. and Allergy, Isfahan, Iran, 13-15 May 1998

Khamesipour A., Phase III efficacy trial of multiple doses of autoclaved *L. major* plus BCG. 1st Product Development Team meeting on Leishmaniasis vaccine, TDR/WHO, 24-27 September 1998, Quito, Ecuador.

Khamesipour A., Prevention of cutaneous Leishmaniasis and progress in vaccine development. 4th Intern. Cong. in Dermat. 8-10 Oct. 1997 Tehran, Iran.

Khamesipour A., Hejazi H., Torabi Z., Nilforoushzadeh MA., Dowlati Y.

Safety and immunogenicity of three injections of autoclaved *L. major* in leishmanin negative and positive school children.

1ST World Congress on Leishmaniasis, May 5-9, 1997 Istanbul, Turkey

Khamesipour A., Hashemi-Fesharaki R., Alimohammadian MH., Bagherzadeh A., Dowlati Y. Comparison of three types of leishmanins: standard, autoclaved and freeze/thawed. 1ST World Congress on Leishmaniasis, May 5-9, 1997 Istanbul, Turkey

Firooz A., Alimohammadian MH., **Khamesipour A.**, Dowlati Y. Safety and immunogenicity trail of three doses of a *Leishmania major* vaccine in adults.

1ST World Congress on Leishmaniasis, May 5-9, 1997 Istanbul, Turkey

Khamesipour A., Phase I-II safety and immunogenicity of multiple doses of autoclaved *L. major* plus BCG in children. WHO/TDR Steering committee meeting, May 2-4, 1997 Istanbul, Turkey

Khamesipour A., Hejazi H., Torabi Z., Nilforoushzadeh MA., Dowlati Y.

Safety and immunogenicity of three injections of autoclaved *L. major* in leishmanin negative and positive school children. Acta Parasitologica Turcica:21(1):28, 1997.

Khamesipour A., Hashemi-Fesharaki R., Alimohammadian MH., Bagherzadeh A., Dowlati Y. Comparison of three types of leishmanins: standard, autoclaved and freeze/thawed. Acta parasitologica Turcica. 21(1):28, 1997

Momeni AZ., Ghassemi RL., Dowlati Y., **Khamesipour A.**, Jalayer T., Emmamjomeh M. Efficacy of killed *Leishmania major* vaccine against natural cutaneous Leishmaniasis in adult and children older than 5 year.

Acta parasitologica Turcica 21(1):11. 1997

Sacks D., **Khamesipour A.**, Alimohammadian MH., Hashemi-Fesharaki R., Bahar K., Modabber F., Dowlati Y. Immune response of Iranian volunteers to single or multiple injections of a killed *Leishmania* plus BCG vaccine.

Acta parasitologica Turcica 21(1):11. 1997

Firooz A., Alimohammadian MH., **Khamesipour A.**, Dowlati Y. Safety and immunogenicity trail of three doses of a *Leishmania major* vaccine in adults.

Acta Parasitologica Turcica:21(1):28, 1997.

Khamesipour A, Hashemi-Fesharki, R., Alimohammadian, M. and Dowlati, Y. Comparison of Specificity and Sensitivity of Two Types of Leishmanin (autoclaved *L. major* and thimerosal treated *L. major*).

Khamesipour A, Hashemi-Fesharki, R., Alimohammadian, M. and Dowlati, Y. Comparison of Specificity and Sensitivity of Two Types of Leishmanin (autoclaved *L. major* and thimerosal treated *L. major*). The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Khamesipour A, Hejazi, H., Alimohammadian, M. and Dowlati, Y., Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Momeni, A., **Khamesipour A**, Jalayer T., Dowlati, Y., Modabber F., The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Khamesipour A, Hejazi, H., Alimohammadian, M. and Dowlati, Y. Induction of partial protection in susceptible Balb/c mice via subcutaneous route of immunization. The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Dowlati, Y., **Khamesipour A**. and Alimohammadian, M. A new candidate region or a phase III *Leishmania* vaccine trial with different schedule. The clinical trials of killed *Leishmania major* vaccine. Amman, Jordan April 15-16, 1996.

Bahar, K., Dowlati, Y., Ehsasi, B., **Khamesipour A**, and Ale-Agha, S. Vaccine trial against zoonotic cutaneous Leishmaniasis (old world Leishmaniasis) in Iran. The clinical trials of killed *Leishmania major* vaccine, Amman, Jordan April 15-16, 1996.

Komeili, A., **Khamesipour A**, Ansarin, H. and Dowlati, Y. The effect of epidermal growth factor on burn patients. American Academy of Dermatology, the Annual meeting, Washington, DC, USA, February 10 - 15, 1996.

Khamesipour A, Pal, S., Peterson, E. M. and de la Maza, L. M. Tubal Infertility in mice as a result of a *Chlamydia trachomatis* MoPn genital infection. Annual Meeting of American Society for Microbiology, Abstract #B284, 1993.

Khamesipour A, E. J. Moticka and M. D. Cooper. Effects of T cell mitogens and cytokines on the infection of the human fallopian tube mucosa. Inter. Congress of Mucosal Immun. Prague, Czechoslovakia 1992.

Khamesipour A, E. J. Moticka and M. D. Cooper. Effects of mitogens on infectivity of the human fallopian tube mucosa by *Chlamydia trachomatis*. Annual Meeting of American Society for Microbiology, Abstract #E68, 1990.

Modabber, F., Nasser M., A. **Khamesipour A**, Alimohammadian M., and M. Kamali, Dept. of Pathobiology, School of Public Health, Tehran Iran. Genetic Susceptibility of Mice to *Leishmania tropica major*: visceral Leishmaniasis in Balb/c Mice. Int. Symposium of the Canadian Society for Immunology. March 1980

VIII. *PUBLICATIONS*

1. Rahi AA, Ali MA., **Khamesipour A**. Comparison of Real time PCR with traditional tools for diagnosis of *Trichomonas vaginalis* in patient with vaginal discharge at Kut city, Iraq. Accepted in Journal of Advances in Biology.
2. Anjomruz M., Oshaghi MA., Pourfatollah AA., Sedaghat MM., Raeisi A., Vatandoost H., **Khamesipour A.**, Mohtarami F., Abai MR., Akbarzadeh K., Rafie F., Besharati M. Preferential feeding success of laboratory reared *Anopheles stephensi* mosquitoes according to ABO blood group status *Acta Tropica*
3. Ali MA. Khamesipour A., Keshavarz Valian H., Rahi AA. Diarrhea caused by *Cryptosporidium parvum* in Kut, Iraq using different methods. Accepted in SJAMS
4. **Khamesipour A**. Therapeutic vaccines for leishmaniasis. *Expert Opin Biol Ther.* 2014 Jul 31:1-9.

5. Davoudi N, **Khamesipour A**, Mahboudi F, McMaster WR. A dual drug sensitive *L. major* induces protection without lesion in C57BL/6 mice. *PLoS Negl Trop Dis*. 2014 May 29;8(5):e2785.
6. **Khamesipour A**. The Need to Teach Vaccine Safety to Basic Scientists and Public Health Officials. *Current Drug Safety*, 2014, 9, 000-000
7. Bakhshi H, Borhani N, Mohebal M, **Khamesipour A**, Abai MR, Hajjaran H, Tajedin L, Rassi Y, Akhavan AA, Mohtarami F, Oshaghi MA. Interleukin 4 (IL-4) gene promoter polymorphisms in *Rhombomys opimus*, the main reservoir of zoonotic cutaneous Leishmaniasis. *Cytokine* (2014) Oct 24. doi:pii: S1043-4666(13)00713-8.
8. Firouzmand H, Badiie A., **Khamesipour A.**, Heravi Shargh V., Alavizadeh S.H., Abbasi A., Jaafaric MR., Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble *Leishmania* antigen (SLA) *Acta Tropica* (2014)
9. Moosavian Kalat S.A., **Khamesipour A.**, Bavarsad N., Fallah M., Khashayarmanesh Z., Feizi E., Neghabi K., Abbasi A., Jaafari M.R. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of *L. major* lesion in BALB/c mice. *Exp Parasitol*. 2014 Aug;143:5-10.
10. Anjomruz M, Oshaghi MA, Pourfatollah AA, Sedaghat MM, Raeisi A, Vatandoost H, **Khamesipour A**, Abai MR, Mohtarami F, Akbarzadeh K, Rafie F, Besharati M. Preferential feeding success of laboratory reared *Anopheles stephensi* mosquitoes according to ABO blood group status. *Acta Trop*. 2014 Aug 21;140C:118-123.
11. Hoseini SG, Javanmard SH, Hejazi SH, Rafiei L, Zarkesh SH, Karbalaii K, **Khamesipour A**. Comparison of immune regulatory factors in acute and chronic lesions of cutaneous leishmaniasis due to *Leishmania major*. *J Res Med Sci*. 2014 Mar;19(Suppl 1):S36-40.
12. Mortazavi H, Soori T, **Khamesipour A**, Khatami A, Vasheghani-Farahani A. Co-existence of cutaneous leishmaniasis with pleural effusion: a case report from Iran. *Acta Med Iran*. 2014;52(3):231-3.
13. Mortazavi H, Esmaili N, Khezri S, **Khamesipour A**, Vasheghani Farahani I, Daneshpazhooh M, Rezaei N. The Effect of Conventional Immunosuppressive Therapy on Cytokine Serum levels in Pemphigus Vulgaris Patients. *Iran J Allergy Asthma Immunol*. 2014 Jun;13(3):174-83.
14. Jabini R, Jaafari MR, Vahdati Hasani F, Ghazizadeh F, **Khamesipour A**, Karimi G. Effects of Combined Therapy with Silymarin and Glucantime on Leishmaniasis Induced by *Leishmania major* in BALB/c Mice. *Drug Res (Stuttg)*. 2014 Mar 12.
15. Aflatoonian MR, Sharifi I, Hakimi Parizi M, Fekri AR, Aflatoonian B, Sharifi M, Khosravi A, **Khamesipour A**, Sharifi H. A prospective cohort study of cutaneous leishmaniasis risk and opium addiction in south eastern Iran. *PLoS One*. 2014 Feb 20;9(2):e89043.
16. Hajimohammadi B., Dehghani A., Moghadam Ahmadi M., Eslami G., Oryan A., **Khamesipour A**. Prevalence and species identification of *Sarcocystis* in raw hamburgers distributed in Yazd, Iran using PCR-RFLP. *Journal of Food Quality and Hazards Control* 1 (2014) 15-20.
17. Rahi A. A., Ali MA. Keshavarz Valian H., Mohebal M., **Khamesipour A**. Seroepidemiological Studies of Visceral Leishmaniasis in Iraq. *Scholars Journal of Applied Medical Sciences (SJAMS)* ISSN 2320-6691 (Online).
18. Eslami G., Anvari H., Ebadi M., Nabipour Y., Mirzaei F., Gholamrezaei M., and **Khamesipour A.**, The changing profile of cutaneous leishmaniasis agent in a central province of

Iran. Tanzania J. of Health Research. <http://dx.doi.org/10.4314/thrb.v15i1.5> Volume 15, Number 1, January 2013.

19. Kochhar S, Rath B, Seeber LD, Rundblad G, **Khamesipour A**, Ali M; Vienna Vaccine Safety Initiative. Introducing new vaccines in developing countries. *Expert Rev Vaccines*. (2013) Dec;12(12):1465-78. doi: 10.1586/14760584.2013.855612.
20. Tolouei S, Hejazi SH, Ghaedi K, **Khamesipour A**, Hasheminia SJ. TLR2 and TLR4 in Cutaneous Leishmaniasis Caused by *Leishmania major*. *Scand J Immunol*. (2013) Nov;78(5):478-84. doi: 10.1111/sji.12105.
21. Bonhoeffer J, Imoukhuede B, Aldrovandi G, Bachtiar NS, Chan ES, Chang S, Chen RT, Fernandopulle R, Goldenthal KL, Heffelfinger JD, Hossain S, Jevaji I, **Khamesipour A**, Kochhar S, Makhene M, Malkin E, Nalin D, Prevots R, Ramasamy R, Sellers S, Vekemans J, Walker B, Wilson P, Wong V, Zaman K, Heininger U; for the Brighton Collaboration Clinical Trial Protocol Working Group. Template protocol for clinical trials investigating vaccines-Focus on safety elements. *Vaccine* (2013),.02.041.
22. Kazemi-Rad E, Mohebbali M, Erfan M.B.K, Saffari M, Raoofian R, Hajjaran H, Hadighi R, **Khamesipour A**, Heidari M. Identification of antimony resistance markers in *Leishmania tropica* field isolates through a cDNA-AFLP approach. *Exp Parasit*. (2013)135 (2), pp. 344
23. Rezaei Riabi T, Sharifi I, Miramin Mohammadi A, **Khamesipour A**, Hakimi Parizi M. Evaluation of a possible synergistic effect of meglumine antimoniate with paromomycin, miltefosine or allopurinol on in vitro susceptibility of *Leishmania tropica* resistant isolate. *Ir J Parasit*. (2013) 8 (3), pp. 396.
24. Firouzmand H, Badiie A, **Khamesipour A**, Heravi Shargh V, Alavizadeh S.H, Abbasi A, Jaafari M.R. Induction of protection against Leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble *Leishmania* antigen (SLA). *Acta Tropica* (2013).
25. Kheirandish, F., Sharafi, A.C., Kazemi, B., Bandehpour, M., Tarahi, M.J., **Khamesipour, A**. First molecular identification of *Leishmania* species in a new endemic area of cutaneous Leishmaniasis in Lorestan, Iran. *Asian Pacific Journal of Tropical Medicine* (2013) 6 (9) , pp. 713
26. Chavoshian, O., Biari, N., Badiie, A., **Khamesipour, A.**, Abbasi, A., Saberi, Z., Jalali, S.A., Jaafari, M.R. Sphingomyelin liposomes containing soluble leishmania major antigens induced strong Th2 immune response in BALB/c mice. *Iranian Journal of Basic Medical Sciences* (2013) 16 (9) , pp. 965.
27. Kazemi-Rad, E., Mohebbali, M., Khadem-Erfan, M.B., Hajjaran, H., Hadighi, R., **Khamesipour, A.**, Rezaie, S., Saffari, M., Heidari, M. Overexpression of ubiquitin and amino acid permease genes in association with antimony resistance in *Leishmania tropica* field isolates. *Parasitology* (2013) 51 (4) , pp. 413
28. Khatami, A., Talaee, R., Rahshenas, M., **Khamesipour, A.**, Mehryan, P., Tehrani, S., Dowlati, Y., Firooz, A. Dressings Combined with Injection of Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial. *PLoS ONE* (2013) 8 (6).
29. Kheirandish F., Bandehpour M., Davoudi N., Mosaffa N., Dawood S., Kazemi B., Haghighi A., **Khamesipour A.**, Mahboudi, F. Gene regulation of pteridine reductase 1 in leishmania promastigotes and amastigotes using a full-length antisense construct. *Ir J. of Parasitology* (2013) 8 (2) , pp. 190.
30. Barati M., Mohebbali M., Alimohammadian M.H., **Khamesipour A.**, Akhoundi B., Zarei Z. Canine visceral Leishmaniasis: seroprevalence survey of asymptomatic dogs in an endemic area of northwestern Iran. *Journal of Parasitic Diseases* (2013), pp. 1
31. Alvar J., Croft S., Kaye P., **Khamesipour A**, Sundar S., Reed SG. Case Study For Vaccine Against Leishmaniasis, *Decade of Vaccines, Vaccine Supplement* (2013), *Vaccine*.
32. Badiie A, Heravi Shargh V., Khamesipour A., Jaafari MR. Micro/nanoparticle adjuvants for antileishmanial vaccines: Present and future trends. *Vaccine* Volume 31, Issue 5, 21 January 2013, Pages 735–749.
33. Mir Amin Mohammadi, A., **Khamesipour, A.**, Khatami, A., Javadi, A., Nassiri-Kashani, M., Firooz, A., Dowlati, Y., Behnia, M., Eskandari, S.E. Cutaneous Leishmaniasis in suspected patients referred

- to the Center for Research and Training in Skin diseases and Leprosy, Tehran, Iran from 2008 to 2011. Iranian Journal of Parasitology, 2013, 8 (3) , pp. 430.
34. Yarmohammadi, M.E., Hassan, Z.M., Mostafaie, A., Ebtekar, M., Yaraee, R., Pourfarzam, S., Jalali-Nadoushan, M., **Khamesipour, A.**, Faghihzadeh, S., Sharifnia Z., Naghizadeh MM., Ghazanfari, T. Salivary levels of secretory IgA, C5a and alpha 1-antitrypsin in sulfur mustard exposed patients 20 years after the exposure, Sardasht-Iran Cohort Study (SICS). International Immunopharmacology 17 (2013) 952–957.
 35. Askari N., Vaez-Mahdavi MR., Moaiedmohseni S, **Khamesipour A.**, Soroush MR., Moin A., Jalaie S., Ghazanfari Z., Faghihzadeh E., Ghazanfari T. Association of chemokines and prolactin with cherry angioma in a sulfur mustard exposed population— Sardasht-Iran cohort study, International Immunopharmacology 17 (2013) 944–951.
 36. Ghasemi, H., Mostafaie, A., Yaraee, R., Hassan, Z.M., Rezaei, A., Mahmoudi, M., Faghihzadeh, S., Soroush, MR., Ardestani SK., Babaei M., Jalali-Nadoushan M., **Khamesipour A.**, Ghassemi-Broumand M., Ghazanfari, T. Association of serum immunoglobulins levels and eye injuries in sulfur mustard exposed: Sardasht-Iran Cohort Study Inter. Immun. 17 (2013) 944–951
 37. Moin, A., **Khamesipour, A.**, Hassan, Z.M., Ebtekar, M., Davoudi, S.-M., Vaez-Mahdavi, M.-R., Soroush, M.-R., Faghihzadeh, S., Ghazanfari, T. Pro-inflammatory cytokines among individuals with skin findings long-term after sulfur mustard exposure: Sardasht-Iran Cohort Study. International Immunopharmacology 17 (2013) 986–990.
 38. Arjmand R., Soleimanifard S., Saberi S., Tolouei S., **Khamesipour A.**, Hejazi S.H. Comparison of protein profile of killed and autoclaved leishmania major using polyacrylamide gel electrophoresis. Journal of Isfahan Medical School ,2013, 30 (221) , pp. 2460.
 39. Badiie A., **Khamesipour A.**, Samiei A., Soroush D., Shargh V.H., Kheiri M.T., Barkhordari F., Robert Mc Master W. (...), Jaafari, M.R. The role of liposome size on the type of immune response induced in BALB/c mice against Leishmaniasis: rgp63 as a model antigen. Experimental parasitology 132 (4) , pp. 403
 40. Keshavarz Valian H., Nateghi Rostami M., Tasbihi M., Miramin Mohammadi A., Eskandari SE., Sarrafnejad A., **Khamesipour A.** CCR7⁺ Central and CCR7⁻ Effector Memory CD4⁺ T Cells in Human Cutaneous Leishmaniasis .J Clin Immunol (2013) 33:220–234
 41. Hejazi SH, Hoseini SG, Javanmard SH, Zarkesh SH, **Khamesipour A.** Interleukin-10 and Transforming Growth Factor- β in Early and Late Lesions of Patients with Leishmania major induced Cutaneous Leishmaniasis. Iranian J Parasitol: Vol. 6, No.2, 2012, pp.53-60.
 42. **Khamesipour A.**, Jafari Shakib R. Response to letter to editor. Transfusion and Apheresis Science 2012, 47 (3) , pp. 371.
 43. Latifynia, A., **Khamesipour, A.**, Bokaie, S., Khansari, N. Antioxidants and proinflammatory cytokines in the sera of patients with cutaneous Leishmaniasis Iranian Journal of Immunology (2012) 9 (3) , pp. 208
 44. Shargh VH., Jaafari MR., **Khamesipour A.**, Jaafari I., Jalali SA., Abbasi A., BadiieA., Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of Leishmaniasis. 2012 Vaccine
 45. **Khamesipour A.**, Nateghi Rostami M., Tasbihi M., Miramin Mohammadi A., Shahrestani T., Sarrafnejad A., Sohrabid Y., Eskandaria SE., Keshavarz Valiane H. Phenotyping of circulating CD8⁺ T cell subsets in human cutaneous Leishmaniasis. Microbes and Infection (2012) 1-10.
 46. Rath B., Ali M., Codarini G., Elemuwa C., **Khamesipour A.**, Maurer W. Mworozzi E., Rundblad G., Varughese S. Kochhar S. Editorial, Promoting Evidence-based Vaccine Safety Research and Communication—The Vienna Vaccine Safety Initiative, J. of Trop. Pediatrics, VOL. 58, NO. 3, 2012
 47. Golali E., Jaafari MR., **Khamesipour A.**, Abbasi A., Saberi Z., Badiie A., Comparison of *in vivo* adjuvanticity of liposomal PO CpG ODN with liposomal PS CpG ODN: Leishmaniasis as a model. Iranian Journal of Basic Medical Sciences. Vol. 15, No. 5, Sep-Oct 2012, 1032-1045.

48. Muehlhans S., Richard G., Ali M., Codarini G., Elemuwa C., **Khamesipour A**, Maurer W., Mworozzi E., Kochhar s., Rundblad G., Vuitton D., Rath B., Safety reporting in developing country vaccine clinical trials—A systematic review. *Vaccine* 2012, May 9;30(22):3255-65.
49. Eskandari SE., Azimzadeh A., Bahar B., Naraghi ZS., Javadi A., **Khamesipour A.**, Mohamadi M. Efficacy of microwave and infrared radiation in the treatment of the skin lesions caused by leishmania major in an animal model. *Iranian Journal of Public Health* (2012) 41 (8) , pp. 80
50. Tolouei S., GhaediK., **Khamesipour A**, AkbariM., BaghaeiM., Hasheminia SJ., Narimani M., HejaziSH. IL-23 and IL-27 Levels in Macrophages Collected from Peripheral Blood of Patients with Healing Vs Non-Healing Form of Cutaneous Leishmaniasis. *Iranian J Parasitol* (2012) Vol. 7, No.1, page 18.
51. Bavarsad N., Fazly Bazzaz B.S., **Khamesipour A.**, Jaafari M.R, Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice *Acta Tropica* (2012) 124 (1) , pp. 33
52. **Khamesipour A**, Abbasi A., Firooz AR., Mir Amin Mohammadi A., Eskandari SE., Jaafari MR., Treatment of Cutaneous Lesion of 20 Years' Duration Caused By Leishmanization,. 2012 *Indian J. of Dermatology*, March-April 2012, Volume 57 | Issue 2 123-125.
53. Rath B., Ali, M., Elemuwa, C., Maurer W., Bouder F., Mworozzi E., Diedrich S., **Khamesipour A.**, Kochhar, S. Prioritizing polio. *Expert Review of Vaccines* 2012, 11 (12) , pp. 1389.
54. Alavizadeh S.H., Badiie A., **Khamesipour A.**, Jalali S.A., Firouzmand H., Abbasi A., Jaafari M.R. The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by *Leishmania major* in BALB/c mice. *Exp. Paras.* (2012) 132 (3) , pp. 313.
55. Hoseini, S.G., Javanmard, S.H., Zarkesh, S.H., **Khamesipour, A.**, Rafiei, L., Karbalaie, K., Nilfroushzade, M., Baghaei, M., Hejazi, S.H. Regulatory T-cell profile in early and late lesions of cutaneous Leishmaniasis due to *Leishmania major*. *Journal of Research in Medical Sciences* (2012) 17 (6) , pp. 513
56. Shargh VH., Jaafari MR., **Khamesipour A**, Jalali SA., Abbasi A., Badiie A., Cationic liposomes containing soluble *Leishmania* antigens(SLA) plus CpG ODNs induce protection against murine model of Leishmaniasis. *Parasitology Research* (2012) 111 (1) , pp. 105
57. Akhavan AA, Ghods R, Jeddi-Tehrani M, Yaghoobi-Ershadi MR, **Khamesipour A**, Mahmoudi AR. Production and Purification of Anti-Rhombomys opimus Immunoglobulins. *Iran J Arthropod-Borne Dis*, 2011, 5(2): 69–76
58. Pardakhty A, Shakibaie M, Daneshvar H, **Khamesipour A**, Mohammadi-Khorsand T, Forootanfar H., Preparation and evaluation of niosomes containing autoclaved *Leishmania major*: a preliminary study. *J Microencapsul.* 2011 Dec 13.
59. Alavizadeh H, Badiie A, **Khamesipour A**, Jalali SA, Firouzmand H, Abbasi A, Jaafari MR, Alleviation of lesion development induced by Leishmanization in BALB/c mice using LPD nanoparticles containing CpG ODN. *Exper.Parasit* 2011.
60. Tafaghodi M, Eskandari M, **Khamesipour A**, Jaafari MR: Alginate microspheres encapsulated with autoclaved *Leishmania major* (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of Leishmaniasis. *Exp Parasitol*; 2011 Oct;129 (2):107-14.
61. Tolouei S., Hasheminia SJ., Narimani M., **Khamesipour A**, Shatalebi MA., Hejazi SH. Leishmanicidal Activity of Films Containing Paromomycin and Gentamicin Sulfate both In Vitro and In Vivo. *Iranian J Parasitol*: Vol. 6, No.3, 2011, pp.60-65
62. Mahmoudi Rad M., Miramin Mohammadi A., Tousi P., **Khamesipour A**, Ehsani A., Mirdamadi Y., Eskandari SE., Mahmoudi Rad N., Gerami Shoar M., Younespour Sh., Ghasem Z. Identification of *Malassezia* species associated with pityriasis versicolor using PCR-RFLP. *Dermatology and Cosmetic* 2011; 2 (2): 106-114 (Persian Language)
63. **Khamesipour A**, Mohtasham Amiri Z., Amini Kafiabad S., Saadat F., Mansour-ghanaei F, Esteghamati AR., Jafari Shakib R., Frequency of hepatitis B virus DNA in anti-HBc positive, HBsAg negative blood donors in Rasht, north of Iran. Accepted to *Inter. Virology*.
64. Shokri A., Sharifi I., **Khamesipour A.**, Nakhaee N., Fasihi Harandi M, Nosratabadi J., Hakimi

- Parizi M., Barati M. The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of *Leishmania tropica* to meglumine antimoniate. *Parasitol Res*, 2011 DOI 10.1007/s00436-011-2599-6
65. Sharifi I, Nakhaei N, Aflatoonian MR, Hakimi Parizi M, Fekri AR, Safizadeh H, Shirzadi MR, Gooya MM, **Khamesipour A**, Nadim A., Cutaneous Leishmaniasis in Bam: A Comparative Evaluation of Pre- and Post- Earthquake Years (1999-2008). *Iranian J Public Health*, Vol. 40, No.2, 2011, pp.49-56.
66. Brzeziński Piotr, Wollina Uwe, Poklękowska Katarzyna, **Khamesipour A**, Herrero Gonzalez Jose Eugenio, Bimbi Cesar, Di Lernia Vito, Karwan Krzysztof, *Dermatology Eponyms-Phenomen/Sign-Lexicon (D) N Dermatol Online*, 2011; 3(2):158-170.
67. Hamidizadeh N., Barikbin B., Yousefi M., Sahraei A., **Khamesipour A**, Younespour Sh., Sadeghitehrani H., The effect of different concentrations of topical podophyllin on cutaneous Leishmaniasis. *Vol. 14, No. 56, Summer 2011*
68. Eslami G., Frikha F., Salehi R., **Khamesipour A**, Hejazi H., Nilfroushzadeh MA., Cloning, expression and dynamic Cloning, expression and dynamic simulation of TRYP6 from *Leishmania major* (MRHO/IR/75/ER). *Mol Biol Rep* (2011) 38:3765–3776.
69. **Khamesipour A**, Mohammad Hossein Ghoorchi, Khatami, AR., Eskandari SE., Javadi A., Hamed Zartab, Maryam Sarraf-Yazdy, Firooz AR., Comparison of efficacy of intralesional injection of meglumine antimoniate once-weekly with twice-weekly in the treatment of anthroponotic cutaneous Leishmaniasis in Mashhad: a randomized clinical trial, *Dermat. Cosmetic* 2011; 2(1): 1-8 (Persian Language)
70. Kheirandish F., Delfan B., Farhadi S., Ezatpour B., **Khamesipour A**, Kazemi B., Ebrahimzade F. and Rashidipour M., The effect of *Satureja khuzestanica* essential oil on the lesions induced by *Leishmania major* in BALB/c mice, *Afr. J of Phar. Pharm*, May 2011 Vol. 5(5), pp. 648-653.
71. The Working Group on Research Priorities for Development of Leishmaniasis Vaccines and Carlos Henrique Nery Costa, Nathan Peters, Sandra Regina Maruyama, Eldo Cardoso de Brito Jr., Isabel Kinney Ferreira de Miranda Santos, Vaccines for the Leishmaniasis: Proposals for a Research Agenda, Questions and Issues Raised During the International Symposium on Leishmaniasis Vaccines. Olinda, Brazil, March 9-11, 2009. *PLoS Neglected Tropical Dis*. March 2011, Volume 5, Issue 3, e943.
72. Sharifi I., Poursmaelian S., Aflatoonian MR., Fotouhi Ardakani R., Mirzaei M., Fekri AR., **Khamesipour A**, Hakimi Parizi M., Fasihi Harandi M, Emergence of a new focus of anthroponotic Cutaneous Leishmaniasis due to *Leishmania tropica* in rural communities of Bam district after the earthquake, Iran., *Trop. Med. Inter. Health*, 2011, April, 16 (4) 510–513
73. Tafaghodi M., **Khamesipour A**, Jaafari, MR. Immunization against Leishmaniasis by PLGA nanospheres encapsulated with autoclaved *Leishmania major* (ALM) and CpG-ODN, *Parasitol Res* (2011) 108:1265–1273
74. **Khamesipour A**, Khatami, AR., Sharifi I., Bahrami M., Javadi A., Eskandari SE., Firooz AR., Fekri AR., Aflatoonian MR. Comparison of the efficacy of weekly vs. twice a week intralesional injections of meglumine antimoniate in the treatment of anthroponotic cutaneous Leishmaniasis: a randomized clinical trial. *Dermat. Cosmetic* 2010; 1(4): 155-161 (Persian Language)
75. Akhavan AA, Yaghoobi-Ershadi MR, **Khamesipour A**, Mirhendi H, Alimohammadian MH, Rassi Y, Arandian MH, Jafari R, Abdoli H, Shareghi N, Ghanei M, Jalali-zand N., Dynamics of *Leishmania* infection rates in *Rhombomys opimus* (Rodentia: Gerbillinae) population of an endemic focus of zoonotic cutaneous Leishmaniasis in Iran. *Bull Soc Pathol Exot*. 2010 May; 103 (2):84-9.
76. Nateghi Rostami M., Keshavarz H., Edalat R., Sarrafnejad A., Shahrestani T., Mahboudi F., **Khamesipour A**, CD8⁺ T cells as a source of IFN- γ production in human cutaneous Leishmaniasis. *PLoS Neglected Tropical Dis*. October 2010, 4, 10, 845.
77. Tafaghodi, M., Eskandari, M., Kharazizadeh, M., **Khamesipour, A.**, Jaafari, M.R. Immunization against Leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved *Leishmania major* (ALM) and Quillaja saponins. *Tropical Biomedicine* 2010, 27(3): 639–650 (2010).
78. Akhavan AA., Mirhendi H., **Khamesipour A**, Alimohammadian MH., Rassi Y., Bates P., Kamhawi S., Valenzuela JG., Arandian MH., Abdoli H., Jalali-zand N., Jafari R., Shareghi N., Ghanei M., Yaghoobi-Ershadi MR. *Leishmania* species: *Leishmania* species: Detection and identification by nested PCR assay

from skin samples of rodent reservoirs. *Exp Parasitol.* 2010 Dec;126 (4):552-6.

79. Nateghi Rostami M., Kesharz Valian H., **Khamesipour A**, Immune response evaluation against an experimental vaccine of Alum precipitated autoclaved *Leishmania major* (Alum-ALM) mixed with BCG or *Mycobacterium vaccae* in BALB/c mice. *Tropical Biomedicine* 27(1): 89–102 (2010).

80. Akhavan AA, Yaghoobi-Ershadi MR., Mirhendi H., Alimohammadian M H., Rassi Y., Shareghi N., Jafari R., Arandian MH. Abdoli H., Ghanei M., Jalali-zand N, **Khamesipour A.**, Molecular epizootiology of rodent Leishmaniasis in a hyperendemic area of Iran: what else you should know. *Iranian J Publ Health*, Vol. 39, No.1, 2010, pp.1-7.

81. Nateghi Rostami M., Keshavarz H., Eskandari SE., Miramin Mohammadi A., Shahrestani T., Sarrafnejad A., **Khamesipour A**, Differential *in vitro* CD4⁺/CD8⁺T-cell response to live vs. Killed *Leishmania major*. *Parasite Immunology*, 2010, 32, 101–110.

82. Fata A., **Khamesipour A**, Mohajery M., Hosseininejad Z., Afzalaghahi M., Berenji F., Ganjbakhsh M., Akhavan AA., Eskandari SE., Amin-mohammadi A., Whatman paper (FTA cards) for storing and transferring *Leishmania* DNA for PCR examination. *Iran J Parasitol.* (4), No.4, 2009, pp.37-42.

83. Sharifi I., Fekri AR., Aflatonian MR., **Khamesipour A**, Dowlati Y., Nadim A., Modabber F. *Leishmaniasis recidivans* among school children in Bam, South-east Iran, 1994-2006, *Inter. J. Der.* 2010, 49, 557–561.

84. Hejazi H., Tasbihi M., Jaafari MR., Badiie A., Pestechian N., **Khamesipour A.**, The role of liposomal CpG ODN on the course of *L. major* infection in BALB/c mice. *Iran J Parasitol:* Vol. 5, No.1, 2010, pp. 47-54.

85. Badiie A., Jaafari MR., **Khamesipour A**, Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., Mc Master RW., Mahboudi F., The role of liposome size on the type of immune response and protection rate induced against Leishmaniasis in BALB/c mice: rgp63 as a model antigen. *J. of Drug Targeting.*

86. Honoré N., Monot M., Garnier T., Zidane N., Sherafi D., Paniz-Mondolfi A., Matsuoka M., Taylor GM., Donoghue HD., Bouwman A., Mays S., Watson C., Lockwood D., **Khamesipour A.**, Dowlati Y., Jianping S., Rea TH., Vera-Cabrera L., Stefani M., Banu S., Macdonald M., Raj Sapkota B., Spencer JS., Brennan PJ., and Cole Stewart T., Phylogeography of leprosy, *Nature Genetics.*2009;doi:10.1038.477

87. Honoré N., Monot M., Garnier T., Zidane N., Sherafi D., Paniz-Mondolfi A., Matsuoka M., Taylor GM., Donoghue HD., Bouwman A., Mays S., Watson C., Lockwood D., **Khamesipour A.**, Dowlati Y., Jianping S., Rea TH., Vera-Cabrera L., Stefani M., Banu S., Macdonald M., Raj Sapkota B., Spencer JS., Brennan PJ., and Cole Stewart T., Supplementary information for Comparative genomic and phylogeographic analysis of *Mycobacterium leprae*. *Nature Genetics:*10.1038.477.

88. Jaafari MR, Bavarsad N, Fazly Bazzaz B.S., Samiei A, Soroush D, Ghorbani S., Lotfi Heravi MM., **Khamesipour A**, Effect of Topical Liposomes Containing Paromomycin Sulfate in the Course of *Leishmania major* Infection in Susceptible BALB/c Mice. *Antimicrobial Agents and Chemotherapy.* 2009, p. 2259–2265 Vol. 53, No. 6

89. Hejazi SH, Zia-Jahromi N, Bandehpour M, Eslami G, Salehi R, **Khamesipour A.**, Kazemi B., Gene Cloning of Iranian *Leishmania major* Mannose-1-Phosphate Guanyltransferase. *Iranian J Parasitol:* Vol. 4, No.3, 2009, pp.1-9

90. Khanjani, N., González, U., Leonardi-Bee, J., Mohebbali, M., Saffari, M., **Khamesipour A.** Vaccines for preventing cutaneous Leishmaniasis, *Cochrane Database of Systematic Reviews* (1), Art. No. CD007634

91. Noazin S., **Khamesipour A**, Moulton L., Tanner M., Nasser K., Modabber F., Sharifi I., Khalil EAG., Velez Bernal ID., Antunes CMF., Smith PG., Efficacy of killed whole-parasite vaccines in the prevention of Leishmaniasis- A meta-analysis, *Vaccine* 2009; 27: 4747-53.

92. Badiie A., Jaafari MR., **Khamesipour A**, Samie A., Soroush D., Tavassoti Kheiri M., Barkhordari M., McMaster WR., Mahboudi F., The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of *Leishmania* (rgp63). *Experimental Parasitology* (2009); 121:362–369

93. Badiee A., Jaafari MR, **Khamesipour A**, Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., McMaster RW., Mahboudi F. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): The role of bilayer composition. *Colloids and Surfaces B: Biointerfaces*, 2009, 1-32.
94. Jaafari MR., Bavarsad N., Fazly Bazaz BS., Samiei A., Soroush D., Ghorbani S., Lotfi heravi MM., **Khamesipour A**, The Effect of Topical Liposomes Containing Paromomycin Sulfate (PM) in the Course of Leishmania major Infection in Susceptible BALB/c Mice (AAC01319-08 Version 2), Feb 2009, *Antimicrobial Agents and Chemotherapy (AAC)*, June 2009, p. 2259–2265.
95. Jafari Shakib R. J., Shokrgozar M.A., Nassiri-Kashani M., Malakafzali B., Nikbin B., and **Khamesipour A**, Plasma sCD26 and sCD30 levels in cutaneous Leishmaniasis. *Acta Tropica* 2009, 109, 61-63.
96. Gidudu J, Kohl KS, Halperin S, Hammer SJ, Heath PT, Hennig R, Hoet B, Rothstein E, Schuind A, Varricchio F, Walop W, Michael Marcy S, Heining U, Braun M, Keller Stanislawski B, Blum M, Leroy O, Bayas JM, Berardi S, Brown A, Burns G, Burroni D, Chatterjee A, da Costa C, de Bruijn I, Grenier JL, Hohenboken M, Iskander J, Jackson L, **Khamesipour A**, King A, Kroger A, Lawrence DN, Nalin D, Nisslein T, Nokleby H, Oleske JM, Sillan F, Sparks R, Tao L, Vilella A, Warden B, Wong V, Zaroni G, Zorn J, Chen P, Compingbutra A, Gomez O. A local reaction at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data, *Vaccine* 26 (2008) 6 8 0 0–6 8 13.
97. Eslami G., Salehi R., Hejazi H., **Khamesipour A**, Kazemi B., Cloning and Expression of TRYP6 Gene from Leishmania major (MRHO/IR/75/ER). *Iranian J Arthropod-Borne Dis.*, (2008), 2(1): 7-15.
98. Nateghi Rostami M. **Khamesipour A**, Eskandari SE., Miramin Mohammadi A., Sarraf Nejad A., Keshavarz H. Flow Cytometric Analysis of Leishmania Reactive CD4⁺/CD8⁺ Lymphocyte Proliferation in Cutaneous Leishmaniasis. *Iranian J Parasitol: Vol. 3, No.4, 2008*, pp. 9-18.
99. Noazin S., Modabber F., **Khamesipour A**, Smith PG., Moulton L H., Nasseri K., Sharifi I., Khalil Eltahir AG., Velez Bernal ID., Antunes Carlos MF., Kieny MP., Tanner M., First generation Leishmaniasis vaccines: A review of field efficacy trials, *Vaccine*. 2008 Dec 9;26(52):6759-67.
100. Khatami A., Firooz A., Gorouhi F, **Khamesipour A**, Dowlati Y. Cutaneous Leishmaniasis. *Lancet Infectious Diseases* 2008; 8(8):458.
101. Lieke T., Nylén S., Eidsmo L.W., Mc Master R., Miramin Mohammadi A., **Khamesipour A**, Berg L., Akuffo H., Leishmania surface protein gp63 binds directly to human NK cells and inhibits proliferation. *Clin. Exper. Immunology*, August 2008, 153(2):221-230.
102. Jafari Shakib R., Ajdary S., Mohtasham Amiri Z., Miramin Mohammadi A., Nourijelyani K., Mortazavi H., Shokrgozar MA., Nikbin B., **Khamesipour A**, CD26 expression on CD4⁺ T cells in patients with cutaneous Leishmaniasis. *Clinical Experimental Immunology* 2008, 153: 31–36.
103. Kesharz Valian H., Khoshabe Abdollah Kenedy L., Nateghi Rostami M., Miramin Mohammadi A., **Khamesipour A**, Role of Mycobacterium vaccae in the protection induced by first generation Leishmania vaccine against murine model of Leishmaniasis. *Parasitology Research* (2008) 103:21–28.
104. Badiee A., Jaafari MR., Samieia A., Soroush D., **Khamesipour A.**, Co-encapsulation of CpG ODN with rLmSTII in liposome enhances immune response and protection in immunized BALB/c mice against Leishmaniasis, *Clin. & Vaccine Immunology*, April 2008, p. 668-674, Vol. 15, No. 4.
105. Jaafari MR. Badiee A., **Khamesipour A**, Samiei A., Soroush D., Tavassoti Kheiri M., Barkhordari F., McMaster R., Mahboudi F. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. *Vaccine* 25 (2007) 6107–6117.
106. Alimohammadian MH, Darabi H., Malekzadeh S., Mahomoodzadeh-Niknam H., Ajdary S., **Khamesipour A.**, Bahonar A, Mofarrah AR., Exposure to Leishmania major Modulates the Proportion to CD4⁺ Cells Without Affecting Cellular Immune Responses. *Microbial Immun.* 2007, 51(10), 1003-1011.
107. Daneshpazhoo M., Chams-Davatchi C, **Khamesipour A**, Mansoori P, Taheri A, Firooz A, Mortazavi H., Esmaili N., Dowlati Y. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian

patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity. JEADV 2007, 21:1319-1324.

108. Hadighi R., Boucher P., **Khamesipour A.**, Meamar A. R., Roy G., Ouellette M., Mohebalı M., Glucantime-resistant *Leishmania tropica* isolated from Iranian patients with cutaneous Leishmaniasis are sensitive to alternative anti *Leishmania* drugs. Parasitol Res (2007) 101:1319–1322.
109. Nassiri Kashani M., Firooz AR., Eskandari SE., Ghoorchi MH., **Khamesipour A.**, Khatami AR., Javadi A., Dowlati Y., Evaluation of meglumine antimoniate effects on liver, kidney and pancreas function tests in patients with cutaneous Leishmaniasis. Eur J Dermatol 2007; 17 (6): 513-515.
110. Rüggeberg, J.U., Gold, M.S., Bayas, J.-M., Blum, M.D., Bonhoeffer, J., Friedlander, S., de Souza Brito, G., Heininger, U., Simpson, N. Bayas MJ., Blum M., Bonhoeffer J., Friedlander S., de Souza Brito G., Gold M. (team leader), Forster J., Heininger U., Imoukhuede B., **Khamesipour A.**, Lajeunesse-Erlewyn M., Martin S., Mäkelä M., Nell P., Pool V., Rüggeberg J., (working group coordinator); Simpson N., Anaphylaxis as an Adverse Event Following Immunization Case Definition & Guidelines for Data Collection, Analysis, and Presentation, The Brighton Collaboration Allergic Reaction Working Group: Vaccine 2007 25 (31), pp. 5675-5684.
111. Ajdary S., Jafari-Shakib R., Riazi-Rad F., Khamesipour A. Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous Leishmaniasis. J of Infection (2007) 55, 75-78.
112. Abedi S., **Khamesipour A.**, Izadi S. HeJazi H., Mikhak M. Effect of *Leishmania gerbili* injection on mice immunization against cutaneous Leishmaniasis caused by *Leishmania major* . Pakistan J Biol. Sci. 2007 10 (1):196-198.
113. Sohrabi Y., Jaafari MR., Badiie A., Hejazi SH., Eskandari SE., Mohammadi AM., Khamesipour A. Evaluation of protection rate and immune response to positive charge liposomes encapsulated with autoclaved *Leishmania major* in murine model of Leishmaniasis. Iranian Journal of Dermatology 2007; 39(10):37-53 (Farsi Language).
114. Badiie A., Jaafari MR., **Khamesipour A.**, *Leishmania major*: Immune response of BALB/c mice immunized by Stress-Inducible protein 1 encapsulated in liposomes, J. Exp. Parasitol. 115 (2007) 127–134.
115. Alimohammadian MH, Khalilollahi SH., **Khamesipour A.**, Dowlati Y. Evaluation of Immunogenecity, Specificity, Sensitivity and Potency of Standard Leishmanin Reagent Produced in Iran, J. of Aerdebil Univ. of Med. Sciences, 6 (3) Autumn 2006 268-277.
116. Nylén S., **Khamesipour A.**, Mohammadi A., Shakib R., Eidsmo L., Satti I., Modabber F., Akuffo H., Surrogate markers of immunity to *Leishmania major* in Leishmanin Skin Test negative individuals from an endemic area revisited. Vaccine 24 (2006) 6944–6954.
117. Jaafari MR., Ghafarian A., Farrokh-Gisour A., Samiei A., Kheiri MT., Mahboudi F., Barkhordari F., **Khamesipour A.**, McMaster WR., Immune response and protection assay of recombinant major surface glycoprotein of *Leishmania*(rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24 (2006) 5708–5717.
118. Jafari-Shakib R., Ajdary S., **Khamesipour A.**, Shokrgozar M., Mortazavi H., Malek Afzali B., Nikbin B. CD26 and CD30 level in cutaneous Leishmaniasis. 2006 J. Med. Sch., Guilan Med. Univ. No 58 (15), 27-32 (Farsi Language).
119. Firooz A., **Khamesipour A.**, Ghoorchi MH., Nassiri-Kashani M., Eskandari SE., Khatami AR., Hooshmand B., Gorouhi F., Rashighi-Firoozabadi M., Dowlati Y., Imiquimod in combination with meglumine antimoniate for cutaneous Leishmaniasis: A randomized assessor-blind controlled trial. Arch Dermatol. 2006;142:1575-1579.
120. Hadighi R., Mohebalı M., Boucher P., Hajjaran H. **Khamesipour A.**, Marc Ouellette. Unresponsiveness to Glucantime treatment in Iranian cutaneous Leishmaniasis due to drug resistant *Leishmania tropica* parasites. PLoS Med 2006;3:e162.
121. Ghazanfari T., Hassan ZM., Khamesipour A., Enhancement of peritoneal macrophage phagocytic activity *Leishmania major* by garlic (*Allium Sativum*) treatment. J Ethnopharmacol 103 (2006) 333–337.
122. **Khamesipour A.**, Rafati S., Davoudi N., Mahboudi F. and Modabber F. Leishmaniasis Vaccine Candidates for Development: Global Overview, Indian J Med Res 123, March 2006, pp 423-438.

123. Badiee A., Jaafari MR., **Khamesipour A**, Samiei A., Sourosh D., Immune response evaluation against Leishmaniasis using liposomes containing rLmST11. *Iranian J. Basic Med. Sciences* 2005 8(28) 215-225 (Persian Language).
124. Musa AM., Khalil EAG., Ismail A., Elhassan M., Fesharki H., **Khamesipour A**, Modabber F., Zijlstra EE., El-Hassan AM., Safety, immunogenicity and possible efficacy of immunochemotherapy of persistent Post Kala-azar Dermal Leishmaniasis. *Sudan J Dermatol* 2005; Vol 3 (2) 63-72.
125. Valizadeh M., Dalimi-Asl AH., Fata A., Jaafari MR., **Khamesipour A**, Mohebbali M., A study on Leishmania species causing cutaneous Leishmaniasis in Mashhad using specific monoclonal antibodies. *Modares J. of Med. Sciences, Fall-Winter* 2005; 7(2):107-113.
126. Badiee A., Jaafari MR., **Khamesipour A**, Samiei A., Sourosh D., Immune response evaluation against Leishmaniasis using liposomes containing rLmST11. *Iranian J. Basic Med. Sciences* 2005 8(28) 215-225 (Persian Language).
127. Nateghi Rostami M., Kesharz Valian H., Mohammadi AM., **Khamesipour A**, Evaluation of protection and immune response after vaccination with Alum-ALM mixed Mycobacterium vaccae or BCG in murine model. *Iranian Journal of Dermatology* 2005; 8(5):363-372 (Farsi Language).
128. **Khamesipour A**, Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., Modabber F. Leishmanization: Use of an old method for evaluation of candidate vaccines against Leishmaniasis. *Vaccine*. 2005 May 25; 23(28):3642-8.
129. Bakhshizadeh M., Hejazi SH., Baghaee M., Jafari F., Ghaioor Z., **Khamesipour A**, The effect of a nitric oxide releaser on healing of Leishmania lesion in animal model. *Iranian Journal of Dermatology* 2005; 8(4):260-265 (Farsi Language).
130. Eidsmo L., Nylen S., **Khamesipour A**, Hedbl MA., Chiodi F., Akuffo H. The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major induced cutaneous Leishmaniasis. *Amer. J. Pathol.* 2005 Apr; 166(4):1099-108.
131. Shazad B., Abbaszadeh B., **Khamesipour A**, Comparison of topical paromomycin sulfate (Twice/Day) with intralesional meglumine antimonate for the treatment of cutaneous Leishmaniasis caused by L. major. *EJD* 2005 (15) 1-3.
132. Firooz A., Khatami A., **Khamesipour A**, Nassiri-Kashani M., Behnia F., Nilforoushzadeh M., Pazoki-Toroudi H., Dowlati Y. Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous Leishmaniasis: A randomized, double-blind, controlled clinical trial. *J. Drugs in Dermatology* 2005 (4) 73-79.
133. Nassiri-Kashani M., Firooz, A., **Khamesipour A**, Mojtahed F., Nilforoushzadeh M., Hejazi H., Bouzari N., Dowlati Y. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous Leishmaniasis. *JEADV* 2005 (19) 80-83.
134. Mohebbalia M., **Khamesipour A**, Mobedi I., Zareia Z., Hashemi-Fesharki R., Double blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral Leishmaniasis in Meshkin-shahr district I.R. Iran. *Vaccine* 2004 (22) 4097-4100.
135. Firooz A, Khatami A, **Khamesipour A**, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, Pazoki-Toroudi H, Dowlati Y. Intralesional injection of 2% zinc sulfate solution in the treatment of acute Old World cutaneous Leishmaniasis: a randomized, double-blind, controlled clinical trial. *Iranian Journal of Dermatology* 2004; 7(4):209-18 (Farsi Language).
136. Mohebbali M., Yaghoobi P., Hooshmand B., **Khamesipour A**, Efficacy of Paromomycin ointment prepared in Iran (Paromo-U) against cutaneous Leishmaniasis caused by Leishmania major in mouse model. *Iranian J. of Dermat. Winter* 2004, Vol. 7, No 2. (Farsi Language).
137. Ahmadi Mousavi, MR., Damghani Ma., Haghdoust, AA. **Khamesipour A**, Opium and Risk of Laryngeal Cancer, *The Laryngoscope*, 2003, 113;1939-43.
138. Mahmoodi M., **Khamesipour A**, Dowlati Y., Rafati S., Momeni AZ., Emanjomeh M., Hejazi H., Modabber F., Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG. *Clinical and Experimental Immunology* 2003, 134:2 p. 303-8.
139. Firooz A., **Khamesipour A**, Dowlati Y., Economic analysis of oral and topical therapies for

onychomycosis of the toenails and fingernails. *Manag Care* 2003, March;12 (3):47-54.

140. Firooz A, **Khamesipour A**, Dowlati Y., Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis. *J Dermat. Treat.* 2003 Jun;14 (2):95-8.

141. Alimohammadian MH., **Khamesipour A**, Darabi H., Firooz AR., Malekzadeh Sh., Bahonar A., Dowlati Y., Modabber F. The role of BCG in immune responses induced by multiple doses of autoclaved *Leishmania major* vaccine injection. *Vaccine* (2002) 3422, 1-7.

142. Izadi, SH., Shahmoradi, A., Khamesipour, A. Hejazi, H., Comparison of cimetidine and glucantime in treatment of Balb/c mice infected with *L. major*. *Med. J. of Sharekord* (4) 34-40, 2002 (Farsi Language).

143. Sharifi I., Fekri A.R., Aflatonian MR., Majdzadeh SR., Ahmadi Mousavi MR., **Khamesipour A**, Nadim A., Tuberculin Skin Test of 11,116 Primary School Children in the Bam City Southern Iran. *Hamdard Medicus*, (XLV) 1, 27-31, Jan-March 2002.

144. Izadi SH., Shahmoradi A., Khamesipour A. Hejazi H., Comparison of cimetidine and glucantime in treatment of Balb/c mice infected with *L. major*. *Med. J. of Sharekord* (4) 34-40, 2002 (Farsi Language).

145. Mortazavi H., **Khamesipour A**, Halaj, Z., Bakhshi, H., Miramin Mohammadi, A., Comparison of IFN- γ production and leishmanin skin test response in non-healing and self healing cutaneous Leishmaniasis. *Iranian J. of Dermatology* (2002) 5 (3):3-9 (Farsi Language).

146. Habibi, G.R., **Khamesipour A**, Mahboodi F. Cytokine gene expression in healing & non-healing cases of cutaneous Leishmaniasis in response to in vitro stimulation with gp63 using quantitative RT-PCR. *Scand J. Immun.* 54, 414-420, 2001.

147. Firooz A., **Khamesipour A**, Fallah N., Dowlati Y. The effect of treatment with itraconazole on quality of life of patients with toenail onychomycosis. *JEADV*;15 (Suppl. 2): 121-22, 2001.

148. Hejazi H., Nasrifar P., Jahangirnejad AA., Khamesipour A. Identification of Leishmaniaspecies using monoclonal antibodies in Isfahan. *Iranian J. of Dermatology* 4:7-11,2000 (Farsi Language).

149. Gholami AR., **Khamesipour A**, Momeni A., Ghazanfari T., Nilforoushzadeh MA., Daraje Z., Dowlati Y. The effect of 5% garlic in treatment of cutaneous Leishmaniasis; a double blind randomized study. *Iranian J. of Dermatology* 3:2-6, 2000 (Farsi Language).

150. Momeni AZ., Jalayer T., Emamjomeh M., **Khamesipour A**, Zicker F., Labaf-Ghasemi R., Dowlati Y., Sharifi I., Aminjavaheri M., Shafiei A., Alimohammadian MH., Hashemi-Fesharki R., Nasseri K., Godal T. Smith P. Modabber F. A randomized, Double Blind, Controlled Trial of a Killed *L. major* vaccine plus BCG against ZCL in Iran. *Vaccine* (17) 466-472, 1999.

151. Momeni AZ., **Khamesipour A**, Bagherzadeh A., Aminjavaheri M., Comparison of different antigens for leishmanin skin test in patients with cutaneous Leishmaniasis. *Iranian J. Dermatology* 1999; 3(1):24-30 (Farsi Language).

152. Asilian A., **Khamesipour A**, Modabber F., Leishmaniasis. *Postgraduate Doctor*, 2(5): 174-181, 1998.

153. Mortazavi H., **Khamesipour A**, Ardehali S. Cheilitis with huge bilateral cervical lymphadenopathy suggestive of *Leishmania* lymphadenitis. *Annales de Dermatologie*, vol 125 Sup. 1 p 89. 1998.

154. Sharifi I., Fekri A., Aflatonian M., Nadim, A., Nikian Y., **Khamesipour A**, Cutaneous Leishmaniasis in primary school children in the southeastern Iranian city of Bam. *Bulletin of WHO* 76(3): 289-293, 1998.

155. Sharifi I., Fekri A., Aflatonian M., **Khamesipour A**, Nadim A., Mousavi MRA., Momeni ZA., Dowlati Y., Godal T., Zicker F., Smith P. and Modabber F. Double-blind randomized controlled vaccine trial of a single dose of killed *Leishmania major* plus *Bacillus of Calmette Guerin* (BCG) against anthroponotic cutaneous Leishmaniasis Bam, Iran. *Lancet* May 23, 1998.

156. Dowlati B., Firooz AR., **Khamesipour A**, Lotfi M., Stuart CA., Smith EB., Larijani B., and Dowlati Y., Insulin quantification in patients with soborrheic dermatitis. *Arch Dermatol* 134:1043-1045, Aug 1998.

157. Firooz A., Alimohammadian MH., Khamesipour A. Dowlati Y., Clinical trial of the safety and

- immunogenicity of three doses of a Leishmania vaccine. J. Inves. Der. 110(4):671, April 1998.
158. Hashemi-Fesharki R., Ale-Agha S., Habibi, GR., Manhoury H., Esmail-Nia H., Mohammadi AA., Ahurai P., Vand-Yousefi A., Bahar K., Dowlati Y., **Khamesipour A**, F. Modabber, Production of inactivated wet rural Leishmania vaccine against Leishmania major. Iranian J. Med. Sciences 23:3-4, 74-80, 1998.
159. Sharifi I., Ardehali S., Motazedian H., Aflatonian MR., Fekri AR., Ahmadi-Mousavi MR., Nadim A., **Khamesipour A**, Dowlati Y. and Modabber F. Identification and characterization of Leishmania isolates in school children in Bam, southeastern Iran. Iranian J. of Med. Sci. 22(3-4): 82-89, 1997.
160. Hejazi H., **Khamesipour A.**, Alimohammadian M., Allameh AA., Dowlati Y., A comparison between the protein profile of intact and two preparations of killed Leishmania major by sodium dodecyl sulfate polyacrylamide gel electrophoresis. MJIRI v. 11 (2) 177-180, 1997.
161. Bahar K., Dowlati Y., Shidani B., Alimohammadian MH., **Khamesipour A**, Ehsasi S., Hashemi-Fesharki R., Ale-Agha S., Modabber F. Comparative safety and immunogenicity trial of two killed Leishmania major with or without BCG in human volunteers. Clinics in Dermatology. V. 14 No.5 page 489-495, 1996.
162. **Khamesipour A.** Moticka J. Cooper MD. The effect of T-cell mitogens and cytokines on infectivity of human fallopian tube mucosa by Chlamydia trachomatis. Advances in Mucosal Immun. 1996, 987-990.
163. de la Maza L., Pal S, **Khamesipour A**, Peterson EM, Intravaginal Inoculation of Mice with the Chlamydia trachomatis, Mouse Pneumonitis Biovar Results in Infertility. Inf. & Immunity, May 1994, Vol. 62, No. 5p. 2094-2097.
164. de la Maza LM., PalS., KhamesipourA., Peterson E. M. Induction of infertility by intravaginal inoculation of three inbred strains of mice with the Chlamydia trachomatis mouse pneumonitis biovar in Chlamydial Infections (ed. J. Orfilia et al.) pp537-540, 1994, Societa Editrice Esculapio, Bologna, Italy.
165. **Khamesipour A**, Pal S., Peterson EM., de la Maza LM. Induction of infertility by intravaginal inoculation of three inbred strains of mice with the Chlamydia trachomatis mouse pneumonitis biovar. Infect. Immun. (1994) 62:2094-2097.
166. **Khamesipour A**, Pal S., Peterson E M. and de la Maza LM. The Chlamydia trachomatis mouse pneumonitis biovar induces infertility in strains of mice that differ in their response to the 60 kDa heat shock protein. J. of Rep. Fer. (1994) 101:287-294.
167. **Khamesipour A**, Moticka EJ., Cooper MD., 1995. The effect of T-cell mitogens and cytokines on the infectivity of human fallopian tube mucosa, Adv. Exper. Biol. Med. 371:987-991.
168. Modabber F., Alimohamadian MH., **KhamesipourA.**, Pourmand N., Kamali M., NasseriM.. Genetic Control of Natural Resistance to Infection and Malignancy, p. 29. Academic Press, New York. 1980. (ed. by E. Skamene, P.A.L. Kingshaven and M. Landy).

IX. THESIS DIRECTOR/ADVISOR:

Student name: Mir Amin Mohammadi, Akram
Degree:PhD
CRTSDL, TUMS, 2013-present
Student name: Eskandari, Seyed Ebrahim
Degree:PhD
CRTSDL, TUMS, 2013-present
Student name: Al-Rubaie Abd Al-Kalek, Magda
Degree:PhD
CRTSDL, TUMS, 2012-present
Student name: Rahi, Abdulsadah Abdulabbas
Degree:Post doctorate fellowship; June 2012 to June 2013
Student name: Sohrabi, Yahya

Degree:PhD

Department of Cellular and Molecular Immunology,
Institute of Molecular Genetics,Academy of Sciences of the Czech Republic
23rd faculty of Medicine, CharlesUniversity, Prague, Czech, 2007-incompleted

Student name: Akhavan, Amir Ahmad

Degree:PhD

Department of Medical Entomology and Vector Control, School of Public Health and Institute of Public Health
Research,TehranUniversity of Medical Sciences,
Tehran, Iran, 2006-2010

Student name: Nateghi-Rostami, Mahmoud

Degree:PhD

Institute: School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences,
Tehran, Iran, 2005-2009.

Student name: Sassan, Noazin

Degree:PhD

Institute: University of Basel, STI,2007-2009

Student name: Gilda, Eslami

Degree:PhD

Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan,
Iran

Student name: Badiiee, Ali

Degree:PhD

School of Pharmacy, MashhadUniversity of Medical Sciences, 2002-2007

Student name: Hadighi, Ramtin

Degree:PhD

Department of Parasitology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran, Co-
advisor, 2003-2006

Student name: Jafari-Shakib, Reza

Degree:PhD

Department of Immunology, School of Medicine, TehranUniversity of Medical Sciences, Tehran, Iran, 2002-2006

Student name: Habibi, Gholamreza

Degree:PhD

Institute, Pasteur Institute, Tehran, Iran, 1998-2003

Student name: Nateghi-Rostami, Mahmoud

Degree:MSc

Institute: School of Public Health, TehranUniversity of Medical Sciences, Tehran, Iran, 2001-2003

Student name: Hamidizadeh, Masoumeh

Degree:MSc

Institute:Reinisch Westfalisch Technische Hochschule Aachen, Aachen, Germany 2000-2001

Student name: Hamedivafa, Farzaneh

Degree: Dr Phar.

Institute: School of Pharmacy, MashhadUniversity of Medical Sciences, Mashhad, Iran, 1999-2002

Student name: Khoshabe, Lavina

Degree:MSc

Institute: School of Public Health, TehranUniversity of Medical Sciences, Tehran, Iran, 1998-2000

Student name: Mahmoodi, Majid

Degree: PhD

Institute: Department of Biological Sciences, University of Northern Texas, Denton, Texas, USA. 1995-1999

Student name: Nasrifar, Parvaneh

Degree:MSc

Institute: Department of Biology, School of Sciences, Isfahan University, Isfahan, Iran. 1998-1999

Student name: Mahtab Kalantari

Degree: MSc

Institute: Med.School, Isfahan Univ. of Medical Sciences, Isfahan, Iran. 1998-1999

Student name: Hamidreza Sakhi

Degree: Doctorate in Medical Technology

Institute: Medical School, Isfahan University of Medical Sciences, Isfahan, Iran. 1996-1997

XI. PROJECTS INVOLVED:

A. Principle investigator:

1. Double blind, randomized clinical trial on efficacy of combination of meglumine antimoniate (Glucantime) and topical nano-liposomal paromomycin for the treatment of anthroponotic cutaneous Leishmaniasis (ACL) caused by *Leishmania tropica* (Phase 3), funded by WHO/EMRO Proposal ID No SGS 10/69.
2. Double blind, randomized phase 3 efficacy trial of topical nano-liposomal paromomycin in the treatment of cutaneous Leishmaniasis caused by *L. major* (Phase 3), funded by, School of Pharmacy, Nanotechnology Research Center and Biotechnology Research Center, Mashhad University of Medical Sciences, P.O. Box 91775-1365, Mashhad, Iran and Zoonosis Control Unit, Diseases Management Center, MoH & ME and Center for Research and Training in Skin Diseases and Leprosy, P.O.Box 14155-6383, Tehran 14166, Iran
3. Genetic control of susceptibility to human cutaneous Leishmaniasis, Sponsored by Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, 2009 incompletd.
4. Pilot study of efficacy of topical nano-liposomal Glucantime for the treatment of cutaneous Leishmaniasis caused by *L. tropica*, supported by Mashhad University of Medical Sciences, Mashhad, Iran.
5. Pilot study of efficacy of topical nano-liposomal paromomycin for the treatment of cutaneous Leishmaniasis caused by *L. tropica*, supported by Mashhad University of Medical Sciences, Mashhad, Iran.
6. Study of T lymphocyte subsets in human Leishmaniasis, sponsored by School of Public Health and Institute of Public Health Research, Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, 2007-present.
7. Characterization of Memory T Cells in Human Leishmaniasis, supported by Iran National Science Foundation, ID No 84112/23, 2007- present.
8. Evaluation of efficacy of intra-lesional injections of Glucantime once weekly in comparison with twice weekly in the treatment of acute Anthroponotic Cutaneous Leishmaniasis (ACL), CRTSDL, TUMS, 2007-2008.
9. Randomized open clinical trial on the efficacy of oral miltefosine in comparison with Glucantime in the treatment of anthroponotic cutaneous Leishmaniasis (ACL) caused by *L. tropica*. ID No. SGS05/97, EMRO/TDR. 2006-2008.
10. Phase II-b (safety & immunogenicity) of two doses of Alum-precipitated autoclaved *Leishmania major* (Alum-ALM) plus BCG in healthy volunteers with no response to leishmanin (LST=0), 2006-2008.
11. Phase II-b (safety & immunogenicity) of two doses of Alum-precipitated autoclaved *Leishmania major* (Alum-ALM) plus BCG in healthy volunteers with positive response to leishmanin (LST>0). 2006-2008.
12. Identification of *Phlebotomus papatasi* salivary gland antigens and induction of saliva-mediated immune response in *Rhombomys opimus* and its role in the course of *Leishmania major* infection, sponsored by School of Public Health and Institute of Public Health Research, Center for Research & Training in Skin Diseases & Leprosy, Tehran University of Medical Sciences, 2006-2008.
13. Production, standardization, QC and preclinical testing of live *Leishmania major* as the basis for the establishment of a LZ platform. WHO/IVR. 2006-2008.
14. The critical role of the choice of human volunteers in anti-*Leishmania* vaccine trials. Swedish International Development Cooperation Agency (SIDA), Sweden, 2006-2008.
15. Evaluation of immune response defect in non-healing form of cutaneous Leishmaniasis, joint project between Karolinska & MOH of Iran, 2005-present.

16. Evaluation of immune response development in cutaneous Leishmaniasis. RSG/WHO ID No. 981134, 1998-2003.
17. Leishmanization as live challenge for evaluation of candidate vaccine and protection against Leishmaniasis. TDR/WHO, ID NO. 980827.
18. Phase III efficacy field trial of multiple doses of *Leishmania* vaccine (ALM). TDR/WHO ID No 980461/970190.
19. Safety and immunogenicity of booster dose of *Leishmania* vaccine. TDR/WHO ID NO. 960441
20. Evaluation of autoclaved *Leishmania major* vaccine (ALM) by using leishmanization. MOH, undersecretary of Research
21. Assess of possible induction of a Th1 response in mice immunized with *M. vaccae* mixed with killed *L. major*. Tehran University of Medical Sciences, undersecretary of Research
22. Immunization of susceptible (Balb/c) and resistant (C57BL/6) mice with different liposomes containing *Leishmania* antigens. Tehran University of Medical Sciences, undersecretary of Research
23. Evaluation of Th1/Th2 response using sCD26/sCD30 in cutaneous Leishmaniasis. Center for Research and Training in Skin Diseases and Leprosy, TUMS.
24. Evaluation of possible protection and immune response against Leishmaniasis induced by liposomes co-encapsulated with *Leishmania* Antigen and CpG ODNs in BALB/c mice. Center for Research and Training in Skin Diseases and Leprosy, TUMS.

B. Co-investigator:

1. Frequency of hepatitis B virus DNA in anti-HBc+, HBsAg– blood donors in Rasht, north of Iran, WHO/EMRO.
2. Preparation of LPD nanoparticles containing rgp63 and rLmaC1N as vaccine against cutaneous Leishmaniasis
3. Comparison of combination of Imiquimod cream plus Glucantime vs Glucantime alone in the treatment of Anthroponotic Cutaneous Leishmaniasis (ACL).
4. Field efficacy vaccine trial with Alum precipitated *Leishmania major* Antigen against canine visceral Leishmaniasis (VL) in Meshkin-Shahr district, northwest Iran.
5. The dynamic of amastigote growth within macrophages in human cutaneous Leishmaniasis.
6. Field trial of ALM vaccine efficacy against ACL in 6-8 year old in Bam. TDR/WHO ID No. 970214.
7. Itraconazole in treatment of cutaneous Leishmaniasis. A multicenteric double blind placebo controlled study. JANSSEN-CILA, ID No. JRF/ITR-INT-82.
8. An open trial to evaluate pulse therapy with oral itraconazole in the treatment of disto-lateral onychomycosis. Janssen Pharmaceutica, ID No. A3042
9. Efficacy of killed *Leishmania major* vaccine against natural cutaneous Leishmaniasis in adults and children older than 5. TDR/WHO, ID No. 94008
10. Immunogenicity of killed *Leishmania major* vaccine in human volunteers in non-endemic area. TDR/WHO, ID No. 940181
11. Topical Application of Human Recombinant Epidermal Growth Factor in the Treatment of Burned Patients. Center for Genetic Engineering and Biotechnology, Havana, Cuba.
12. Role of mucosal IgA in *C. trachomatis* genital infection, ID No. PA-93-034 NIH, USA.
13. Collaborator of five more TDR/WHO supported projects.